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INTRODUCTION: 
Oral solid dosage forms: 
Oral route is the most frequently used route for administration of drugs. Tablets and 
capsules represent the majority of dosage forms administered orally. Tablets are solid 
preparations each containing a single dose of one or more active substances. They are 
obtained by compressing uniform volumes of particles or by another suitable manufacturing 
technique, such as extrusion, moulding or freeze-drying (lyophilisation). Tablets are intended 
for oral administration. Some are swallowed whole, some after being chewed, some are 
dissolved or dispersed in water before being administered and some are retained in the mouth 
where the active substance is liberated.1 
 Tablets are usually straight, circular solid cylinders, the end surface of which are flat 
or convex and the edges of which may be beveled. They may have break marks and may bear 
a symbol or other markings. Tablets may be coated or uncoated. Tablets consists of one or 
more active substances with or without excipients such as diluents, binders, disintegrating 
agents, glidants, lubricants, substances capable of modifying the behavior of the preparation 
in digestive tract, colouring matter authorized by the competent authority and flavouring 
substances.1 
 For many disease states the ideal dosage regimen is that by which an acceptable 
therapeutic concentration of drug at the site(s) of action is attained immediately and is then 
maintained constant for the desired duration of the treatment. Therefore, ‘steady-state’ plasma 
concentrations of a drug can be achieved promptly and maintained by the repetitive 
administration of conventional oral dosage form. Although conventional oral dosage form 
releases the complete dosage of drug rapidly in immediate absorption into the systemic 
circulation, it has some severe limitations such as, 
1. Drugs having short half-life require frequent administration 
2. The fluctuations of drug concentration in plasma can lead to under medication or over 
medication. 
3. The fluctuating drug concentration in plasma can lead to precipitation of adverse 
effects especially for a drug with small therapeutic index. 
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4. The typical peak-plasma concentration-time profile of immediate release makes the 
attainment of steady state concentration difficult. 
These limitations led to the development of ‘extended-release’ preparations, for reducing 
the cyclical plasma concentrations. A variety of terms was used to describe these systems. 
• Delayed release 
• Repeat action 
• Prolonged release 
• Sustained release 
• Extended release 
• Controlled release  
• Modified release 
Delayed release: 
  A delayed-release dosage form is designed to release the drug at a time other than 
promptly after administration. The delay may be time based or based on the influence of 
environmental conditions like gastrointestinal pH. (E.g.) enteric-coated tablets, pulsatile-
release capsules. 
Repeat action: 
 Repeat action forms usually contain two single doses of medication, one is released 
fairly soon after administration and the second dose is subsequently released in an extended 
manner at intermittent intervals. 
Prolonged release: 
 It provides drug absorption over a longer period of time than from a conventional 
dosage form. However, there is an implication that onset is delayed because of an overall 
slower release rate from the dosage form. 
Sustained release: 
 It indicates an initial release of drug sufficient to provide a therapeutic dose soon after 
administration, and then a gradual release over an extended period. 
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Extended release: 
 It allows a reduction in dosing frequency from that necessitated by a conventional 
dosage forms so that plasma concentrations are maintained at a therapeutic level for a 
prolonged period of time (usually between 8 and 12 hours). 
Controlled release: 
 These dosage forms release drug at a constant rate and provide plasma concentrations 
that remain invariant with time. 
Modified release: 
 These are the dosage forms whose drug release characteristics of time course and/or 
location are chosen to accomplish therapeutic or convenience objectives not offered by 
conventional forms. 
 It is interesting to note that the USP considers that the terms controlled release; 
prolonged release and sustained release are interchangeable with each other. From a 
biopharmaceutical perspective this is not strictly a concern.2 
CONTROLLED RELEASE DRUG DELIVERY SYSTEMS: 3 
Controlled release drug delivery is one which delivers the drug at a predetermined rate 
locally or systemically for a specified period of time. The goal of a sustained release dosage 
form is to maintain therapeutic blood or tissue levels of the drug for an extended period. 
Sustained release dosage form that provides medication over an extended period of time. 
Controlled release denotes that the system is able to provide some actual therapeutic control, 
whether this is of temporal nature, spatial nature or both. In other words, the system attempts 
to control drug concentrations in the target tissue. This correctly suggests that there are 
sustained release systems that cannot be considered as controlled-release systems. 
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Fig.1.1: Plasma drug concentration – profiles for conventional release formulation, a 
sustained release formulation and a zero – order controlled release formulation. 
 
In general, the goal of a sustained release dosage form is to maintain therapeutic blood 
or tissue levels of the drug for an extended period. This is usually accomplished by attempting 
to obtain zero order release from the dosage form that is independent of the amount of the 
drug in the delivery system (i.e., a constant release rate). 
Advantages of controlled release drug delivery systems 
1. Improved patient compliance. 
2. Reduction in fluctuation in steady-state levels. 
3. Increased safety margin of high potency drugs due to better control of plasma levels. 
4. Maximum utilization of drug enabling reduction in total amount of dose administered. 
5. Better control of disease condition. 
6. Reduced intensity of local or systemic side effects. 
Disadvantages of controlled release drug delivery system 
1. Decrease systemic availability in comparison to immediate release formulation or 
conventional dosage forms. This may be due to 
• Incomplete release  
• Increased first-pass metabolism 
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• Increased instability, 
• Insufficient residence time for complete release 
• Site-specific absorption 
• pH dependent solubility 
2. Retrieval of drug is difficult in case of toxicity, poisoning or hypersensitivity 
reactions. 
3. Reduced potential for dosage adjustment of drugs normally administered in varying 
strengths. 
4. Higher cost of formulation. 
An oral controlled-release system can be designed either as a continuous release system or as 
a pulsed release system. 
1. Continuous release systems release drug continuously over an extended period of 
time. 
2. Pulsatile release systems are characterized by a time period of no release followed by 
a rapid and complete or extended drug release.  
Continuous release system can be classified into two categories- 
1. Continuous-Transit systems 
2. Gastro retentive systems 
Oral controlled release dosage forms can be classified into different ways. One way is to 
distinguish between single-unit dosage forms such as tablets and capsules, and 
multiparticulate dosage forms such as pellets or beads. Controlled release products can be 
classified into3 
• Reservoir systems 
• Osmotic systems 
• Ion-exchange resins 
• Matrix systems 
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GASTRORETENTIVE DRUG DELIVERY SYSTEMS (GRDDS) 4 
 Dosage form with a prolonged gastric residence and controlled drug delivery are 
called as GRDDS. Thus, these dosage forms significantly extend the period of time over 
which the drugs may be release in comparison to other controlled release drug delivery 
systems. Such systems have several applications and advantages- 
1. Effective in delivery of sparingly soluble and insoluble drugs or drugs having low 
solubility at intestinal pH e.g. diazepam. 
2. Effective in the therapy of local disease such as H. pylori infection with drugs such as 
antibiotics or acidity treatment with antacids and misoprostol. 
3. Suitable for administering drugs having absorption window in stomach or upper part 
of  small intestine, e.g.gabapentin, metformin, levodopa, riboflavin, etc. 
4. Suitable for administering drugs unstable in intestine or colon e.g. Captopril. 
5. Enables reduction in variability in drug absorption which is commonly due to 
differences in gastric residence time.  
6. Drugs which undergo abrupt changes in their pH dependent solubility due to factors 
such as food, age and pathophysiological conditions of GI tract. 
Advantages 
1. The bioavailability of therapeutic agents can be significantly enhanced especially for 
those which get metabolized in the upper GIT by this gastro retentive drug delivery 
approach in comparison to the administration of non-gastro retentive drug delivery.  
2. For drugs with relatively short half-life, sustained release may result in a flip-flop 
pharmacokinetics and also enable reduced frequency of dosing with improved patient 
compliance. 
3. They also have an advantage over their conventional system as it can be used to 
overcome the adversities of the gastric retention time (GRT) as well as the gastric 
emptying time (GET). As these systems are expected to remain buoyant on the gastric 
fluid without affecting the intrinsic rate of employing because their bulk density is 
lower than that of the gastric fluids.  
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4. Gastro retentive drug delivery can produce prolong and sustain release of drugs from 
dosage forms which avail local therapy in the stomach and small intestine. Hence they 
are useful in the treatment of disorders related to stomach and small intestine. 
5. The controlled, slow delivery of drug form gastro retentive dosage form provides 
sufficient local action at the diseased site, thus minimizing or eliminating systemic 
exposure of drugs. This site-specific drug delivery reduces undesirable effects of side 
effects. 
6. Gastro retentive dosage forms minimize the fluctuation of drug concentrations and 
effects. Therefore, concentration dependent adverse effects that are associated with 
peak concentrations can be presented. This feature is of special importance for drug 
with a narrow therapeutic index. 
7. Gastro retentive drug delivery can minimize the counter activity of the body leading to 
higher drug efficiency. 
8. Reduction of fluctuation in drug concentration makes it possible to obtain improved 
selectivity in receptor activation.  
9. The sustained mode of drug release from Gastro retentive doses form enables 
extension of the time over a critical concentration and thus enhances the 
pharmacological effects and improves the chemical outcomes. 
 
Disadvantages  
1. These require sufficiently high levels of stomach fluids, for the system to float and to 
work efficiently. 
2. Not suitable for drugs with stability or solubility problem in stomach. 
3. Drugs which undergo extensive first pass metabolism are not suitable candidates. 
4. Drugs with irritant effect also limit the applicability. 
 
Requirements for the gastro retentive formulations 
1. It must form a cohesive gel barrier to facilitate retention. 
2. It must maintain specific gravity lower than gastric contents. 
3. It should release contents slowly to serve as a reservoir. 
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The strategies for delaying drug transit through the GIT fall into one of three categories- 
 
1. Pharmacological approach: involves co-administration or incorporation of a drug into 
the dosage form that delays either gastric emptying e.g. antimuscarinic agents such as 
propantheline or a drug that retards gastric motility e.g. loperamide. 
2. Physiological approach: use of natural materials or fat derivatives such as 
triethanolamine myristate which stimulate the duodenal receptors to slow gastric 
emptying. Use of large amounts of volume filling polymer such as polycarbophil can 
slow gastric emptying. 
3. Pharmaceutical approach: the first two approaches are not used because of toxicity 
problems. The various pharmaceutical approaches or systems used for gastroretention 
can be classified as- 
a. Floating systems 
b. Swelling and expanding systems 
c. Bioadhesive systems 
d. Modified shape systems 
e. High density systems 
GASTRIC EMPTYING AND PROBLEMS 
The stomach is anatomically divided into three parts 
1. Fundus 
2. Body 
3. Antrum (pylorus) 
 The process of gastric emptying occurs both during fasting and fed states. The pattern 
of motility differs markedly in the two states. In the fasted state, it is characterized by an 
interdigestive series of electrical events which cycle both through the stomach and small 
intestine every 2-3 h. This activity is called the interdigestive myoelectric cycle or migrating 
myoelectric complex (MMC), which is often divided into four consecutive phases. 
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Phase-I lasts 45-60 min, is quiescent, with rare low amplitude contractions. 
Phase-II with a length of 30-45 min has intermediate amplitude contractions & involves bile 
secretion. 
Phase-III is also termed ‘housekeeper wave’ & extends for 5-15 min. 
Phase-IV has a length of less than 5 min & connects between the maximal amplitude 
contractions to the basal phase. 
 
Fig 1.2: Phases of migrating myoelectric complex 
Factors affecting gastric retention 
 Density, size, shape of dosage form, concomitant intake of food and drugs such as 
anticholinergic agents(e.g., atropine, propantheline), opiates(e.g., codeine) and prokinetic 
agents (e.g.,metoclopramide, cisapride), and biological factors such as gender, posture, age, 
body mass index, and disease states(e.g., diabetes, Crohn’s disease)  
1. Density  
 The density of a dosage form also affects the gastric emptying rate and determines the 
location of the system in the stomach. Dosage forms having a density lower than the gastric 
contents can float to the surface, while high density systems sink to bottom of the stomach. 
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Both positions may isolate the dosage system from the pylorus. A density of < 1.0 gm/ cm3 is 
required to exhibit floating property. 
2. Food 
 Food affects the GRT of dosage forms depending on its nature, caloric content, and 
the frequency of intake. Nature of meal-feeding of indigestible polymers or fatty acid salts can 
change the motility pattern of stomach to a fed-state, thus decreasing the gastric emptying rate 
and prolonging drug release. Caloric content-GRT can be increased by 4-10 hours with a meal 
that is high in proteins and fats. Frequency of feed- The GRT can increase by over 400 
minutes when successive meals are given compared with a single meal due to the low 
frequency of myoelectric motor complex.  
3. Size  
 Small-size tablets are emptied from the stomach during the digestive phase, while 
larger units are expelled during housekeeper waves. Floating units with a diameter equal to or 
less than 7.5mm had longer GRTs compared to non-floating units. GRT were similar for 
floating and non-floating units having a larger diameter of 9.9mm. 
4. Shape 
 Ring-shaped and tetrahedron-shaped devices have a better gastric residence time as 
compared with other shapes. 
5. Gender 
 Mean ambulatory GRT in males (3.4±0.6 hours) is less compared with their age and 
race matched female counterparts (4.6±1.2 hours), regardless of the weight, height and body 
surface.  
6. Fed or unfed state  
 Under fasting conditions, the GI motility is characterized by periods of strong motor 
activity or the migrating myoelectric complex (MMC) that occurs every 1.5 to 2 hours. The 
MMC sweeps undigested material from the stomach and, if the timing of administration of the 
formulation coincides with that of the MMC, the GRT of the unit can be expected to be very 
short. However, in the fed state, MMC is delayed and GRT is considerably longer. 
 
7. Age – elderly people, especially those over 70, have a significantly longer GRT4 
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GASTRORETENTIVE DRUG DELIVERY SYSTEMS 
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APPROACHES TO GASTRIC RETENTION4 
 
Fig.1.3: showing various approaches for gastro retentive drug delivery systems 
FLOATING DRUG DELIVERY SYSTEMS4 
 Floating drug delivery system or hydrodynamically balanced systems have a bulk 
density lower than gastric contents and thus remain buoyant in the stomach without affecting 
the gastric emptying rate for a prolonged period of time. While the system is floating on the 
gastric contents, the drug is released slowly at a desired rate from the system. After the release 
of the drug, the residual system is emptied from the stomach. This results in an increase in the 
GRT and a better control of fluctuations in plasma drug concentrations. However, besides a 
minimal gastric content needed to allow the proper achievement of the buoyancy retention 
principle, a minimal level of floating force (F) is also required to keep the dosage form 
reliably buoyant on the surface of the meal. To measure the floating force kinetics, a novel 
apparatus used for determination of resultant weight (RW). The RW apparatus operates by 
measuring continuously the force equivalent to F (as a function of time) that is required to 
maintain the submerged object. The object floats better if RW is on the higher positive side. 
Based on the buoyancy mechanism, floating systems are classified as follows 
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1. Effervescent systems 
2. Non-Effervescent systems 
 
 
 
Fig. 1.4: Mechanism of floating drug delivery systems 
 
The magnitude and direction of force/resultant weight (up or down) is corresponding to its 
buoyancy force (F buoyancy) and gravity force (Fgravity) acting on dosage form  
         F = F buoyancy – F gravity 
        
    F = Df g V – Ds g V  
         F = (Df – Ds) g V  
         F = (Df – M/V) g V  
Where,  
            F    = resultant weight of object 
            Df  = Density of Fluid  
            DS = Density of Solid object  
            g    = Gravitational force  
            M  = Mass of dosage form  
            V   = Volume of dosage form 
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So when Ds, density of dosage form is lower, F force is positive gives buoyancy and when it 
is Ds is higher, F will negative shows sinking.  
Plot of F vs. Time is drawn and floating time is time when F approaches to zero from positive 
values. 
 
Fig.1.5: Effect of buoyancy force and gravity force on drug delivery system 
 
Effervescent (gas generating) systems 
 Floatability can be achieved by generation of gas bubbles. These buoyant systems 
utilize matrices prepared with swellable polymers such as polysaccharides (e.g. chitosan), 
effervescent Components (e.g. sodium bicarbonate, citric acid or tartaric acid). The optimal 
stoicheometric ratio of citric acid and sodium bicarbonate for gas generation is reported to be 
0.76: 1. In this system carbon dioxide is released and causes the formulation to float in the 
stomach. Other approaches and materials that have been reported are a mixture of sodium 
alginate and sodium bicarbonate, multiple unit floating dosage forms that generate gas 
(carbon dioxide) when ingested, floating mini capsules with a core of sodium bicarbonate, 
lactose and polyvinyl pyrrolidone (PVP) coated with hydroxyl propyl methylcellulose 
(HPMC), and floating system based on ion exchange resin technology. Bilayer or multilayer 
system has also been designed. Drugs and excipients can be formulated independently and the 
gas generating material can be incorporated into any of the layers. Further modifications 
involve coating of the matrix with a polymer which is permeable to water, but not to carbon 
dioxide4.  
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Fig. 1.6:  (a) multiple unit oral floating dosage system (b) stages of floating mechanism 
A. Penetration of water B. Generation of carbon dioxide and floating C. Dissolution of drug 
 
These systems are further classified as below. 
1. Volatile liquid containing systems 
These are further categorized as 
A. Intragastric floating gastrointestinal drug delivery system: This system contains a 
floatation chamber which contains vacuum or an inert, harmless gas and a 
microporous compartment enclosing drug reservoir. 
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Fig.1.7: showing intragastric floating gastrointestinal drug delivery system 
 
B. Inflatable gastrointestinal delivery system: These systems possess inflatable chamber 
containing liquid ether which gasifies at body temperature to inflate the stomach. 
Inflatable chamber contains bioerodible polymer filament (e.g., copolymer of 
polyvinyl alcohol and polyethylene) that gradually dissolves in gastric fluid and finally 
causes inflatable chamber to release gas and collapse. 
 
 
 
Fig.1.8: showing inflatable gastrointestinal drug delivery systems 
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C. Intragastric-osmotically controlled drug delivery system: It is composed of osmotic 
pressure controlled drug delivery device and an inflatable floating capsule. In the 
stomach, inflatable capsule disintegrates and releases the osmotically controlled drug 
delivery system which contains two components; drug reservoir compartment and 
osmotically active compartment5. 
 
 
 
Fig.1.9: showing Intragastric osmotically controlled drug delivery systems 
2. Matrix tablets 
 It may be formulated as a single layer matrix tablet by incorporating bicarbonates in 
matrix forming hydocolloid gelling agent or a bilayer matrix tablet with gas generating matrix 
as one layer and drug being the second layer. It can also be formulated as triple layer matrix 
tablet with gas generating matrix as one layer and 2 drug layers. 
3. Gas generating systems  
 These systems utilize effervescent compounds like sodium bicarbonate, citric acid and 
tartaric acid. It is further divided as follows. 
A. Floating capsules: These are prepared by formulating mixture of sodium bicarbonate 
and sodium alginate. On exposure to acidic environment, carbon dioxide gas is 
generated which is trapped in the hydrating gel network and makes the system to float. 
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B. Floating pills: These are a type of sustained release formulations which are basically 
multiple unit type of dosage forms. The sustained release pill is surrounded by two 
layers. Outer layer consists of swellable membrane and the inner layer consists of 
effervescent agents. The system swells due to swellable membrane and then sinks. 
Due to presence of effervescent agents, CO2 is released and the system floats. 
C. Floating systems with ion exchange resins: The most common approach for 
formulating these systems involves resin beads loaded with bicarbonate. This is then 
coated with ethyl cellulose which is usually insoluble but permeable to water. This 
causes carbon dioxide to release and the system to float. 
Non effervescent FDDS 
 Non-effervescent floating drug delivery systems are normally prepared from gel-
forming or highly swellable cellulose type hydrocolloids, polysaccharides or matrix forming 
polymers like polyacrylate, polycarbonate, polystyrene and polymethacrylate. In one 
approach, intimate mixing of drug with a gel forming hydrocolloid which results in contact 
with gastric fluid after oral administration and maintain a relative integrity of shape and a bulk 
density less than unity within the gastric environment. The air trapped by the swollen polymer 
confers buoyancy to these dosage forms. Excipients used most commonly in these systems 
include hydroxy propyl methylcellulose (HPMC) polyacrylates, polyvinyl acetate, 
carbopolagar, sodium alginate, calcium chloride, polyethylene oxide and polycarbonates. 
These are further classified as follows  
1. Hydrodynamically balanced drug delivery systems 
 These systems contains drug with gel-forming hydrocolloids meant to remain buoyant 
on the stomach content. These are single-unit dosage form, containing one or more gel-
forming hydrophilic polymers. Hydroxy propyl methylcellulose (HPMC), hydroxyl ethyl 
cellulose (HEC), hydroxyl propyl cellulose (HPC), sodium carboxymethyl cellulose 
(NaCMC), polycarbophil, polyacrylate, polystyrene, agar, carrageenans or alginic acid are 
commonly used excipients to develop these systems. The polymer is mixed with drugs and 
usually administered in hydrodynamically balanced system capsule. The capsule shell 
dissolves in contact with water and mixture swells to form a gelatinous barrier, which imparts 
buoyancy to dosage form in gastric juice for a long period. Continuous erosion of the surface 
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allows water penetration to the inner layers, maintaining surface hydration and buoyancy to 
dosage form. Incorporation of fatty excipients gives low-density formulations reducing the 
erosion. Effective drug deliveries depend on the balance of drug loading and the effect of 
polymer on its release profile. 
2. Microballoons / hollow microspheres  
 These systems contain outer polymer shell loaded with drug. The outer polymer shell 
is made up of polymers like polycarbonate, cellulose acetate, calcium alginate, agar, etc. 
Buoyancy lag time and drug release from the system is dependent on the quantity of polymers 
used in the formulation. These are prepared by emulsion-solvent diffusion method. 
3. Alginate beads 
 These are formulated using calcium and low methoxylated pectin or calcium low 
methoxylated pectin and sodium alginate. In this type, sodium alginate solution is added to 
aqueous solution of calcium chloride which causes precipitation of calcium alginate (beads). 
These beads are then separated and dried by air convection and freeze dried. This results in 
the formation of a porous system which remains buoyant in the stomach. 
4. Layered tablets 
 These may be of single layer or double layered. 
A. Single layered floating tablets: This type of tablets contain drug mixed with gel 
forming hydrocolloids and other excipients. Upon contact with gastric fluids, the 
hydrocolloids swell and maintain bulk density less than one and hence remain buoyant 
in the stomach. 
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Fig. 1.10: intra gastric floating tablet 
 
B. Double layered floating tablets: This type of tablets contains two layers. One of which 
is immediate releasing layer and the other is sustained release layer containing drug 
and hydrocolloids which remains in the stomach for a prolonged period of time. 
 
Fig.1.11: Intragastric floating bilayer tablet 
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NON-FLOATING SYSTEMS 
 These are another class of gastroretentive drug delivery systems which do not float but 
remain in the stomach for a prolonged time period. These systems are formulated by any of 
the following approaches. 
1. Bioadhesive systems: These types of systems adhere to the biological membrane 
(mucosa) of the stomach and maintain intimate contact with the membrane for a 
longer time and hence retains in stomach for its prolonged release. These systems are 
formulated using bioadhesive polymers which can adhere to epithelial surface in the 
stomach. Some of the most promising excipients that have been used commonly in 
these systems include polycarbophil, carbopol, lectins, chitosan, CMC and gliadin, etc. 
2. Swelling systems: These are a type of non-floating gastro retentive drug delivery 
system which when enters stomach swells (due to presence of swellable polymers) to 
an extent that cannot pass through the pyloric sphincter leading to its retention in the 
stomach. 
3. High density systems: These systems possess density greater than the gastric fluids 
due to which the system sinks to the bottom and remains in the stomach. These are 
formulated by coating drug on heavy inert materials like zinc oxide, titanium dioxide, 
iron powder, etc. 
4. Expandable systems: These systems are capable of expanding and retain in the 
stomach for longer periods. These are usually formulated as a capsule containing 
dosage form in folded and compact form. After being exposed to stomach 
environment, capsule shell disintegrates and dosage form expands preventing its exit 
through the stomach. By using a suitable polymer, sustained and controlled drug 
delivery can be achieved. 
5. Evaluation of gastro retentive dosage forms 
6. Evaluation for gastro retention is carried out by means of X-ray and or gamma 
scintigraphic monitoring of dosage form transit in the GI tract4. 
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Tab.1.1: Gastro retentive products available in the market 
 
Brand name Active ingredient 
Cifran OD® Ciprofloxacin 
Madopar® L-dopa & Benserazide 
Valrelease® Diazepam 
Topalkan® Aluminium-Magnesium antacid 
Liquid Gavison® Aluminum hydroxide 
Almagate 
flatcoat® 
Aluminium-Magnesium antacid 
Conviron® Ferrous sulphate 
Cytotec® Misoprostol 
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Tab.1.2: Commonly used drug in formulation of gastro retentive dosage forms 
 
Dosage forms Drugs 
 
Floating 
tablets 
Acetaminophen, acetylsalicylic acid, ampicillin, amoxicillin trihydrate, 
Atenolol, Captopril, cinnerezine, Chlorpheniramine maleate, ciprofloxacin, 
diltiazem, Isosorbide mononitrate, Para amino benzoic acid, prednisolone, 
nimodipine, sotalol, Theophylline, verapamil 
 
Floating 
capsules 
Chlordiazepoxide hydrochloride, diazepam, furosemide, L-dopa and 
Benserazide, nicardipine, misoprostol, Propranolol, pepstatin  
Floating 
microspheres 
Aspirin , griseofulvin, P-nitro aniline, ibuprofen, terfenadine, tranilast 
Floating 
granules 
Diclofenac sodium, indomethacin, prednisolone 
 
 
. 
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REVIEW OF LITERATURE 
M.Parvathi6 formulated and evaluated floating tablets of metformin hydrochloride composed 
of HPMC K 100 and gellan gum by wet granulation method. The developed floating tablets of 
Metformin hydrochloride showed prolonged drug release for at least 12 hrs, thereby 
improving the bioavailability and patient compliance. 
C.Bijumol et al.,7 formulated and evaluated floating tablets of theophylline using gel forming 
hydrophilic polymers such as HPMC K4M, HPMC K100M and HPMC 15 cps. Formulations 
with HPMC K100M & HPMC K4M showed better buoyancy, control of drug release and the 
drug release was similar to that of marketed product. 
K.Ravishankar et al.,8 formulated and evaluated Ciprofloxacin floating tablets using 
different polymer like HPMC K4M, SCMC and carbopol 934 by direct compression 
technique. The experimental results revealed that all formulated tablets were of good quality 
with regard to hardness (3.7 ‐ 4 kg/cm2), thickness (0.3 – 0.35 cm), density (~ 1 g/cm3), 
weight variation (1.3‐ 4.2) and drug content (>90%). As the result of floating capability study 
increasing the effervescent base of tablets from 5% to 10% significantly lower the lag time of 
floating (From about 6 min to 1.5 min) as well as floating duration (From about 21 hrs to 10 
hrs). Invitro drug release showed that all formulation released 80% of the ciprofloxacin 
hydrochloride in 12 hrs study period. It was found that all the formulations were statistically 
significant (p ≤ 0.05).  
Ara N. Patel et al.,9 formulated and evaluated Diltiazem floating tablets were formulated 
with different concentrations of two grades of HPMC polymers (HPMC K4M and HPMC 
K100M) by using wet granulation technique. In-vitro drug release studies were performed and 
drug release kinetics evaluated using the linear regression method was found to follow both 
Higuchi and Korsemeyer and Peppas’ equation. The drug release mechanism was found 
Fickian type in most of the formulations. The formulation containing (HPMC K 4 M) shows 
maximum percentage of drug release (99.87 %) and prolonged release for time period of 
about 12 h, thereby improves the bioavailability and patient compliance. 
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Md. Nazmul Hussain et al.,10  formulated and evaluated Gastro retentive floating tablet of 
Simvastatin using hydrophilic rate retardant by direct compression technique using Methocel 
K4M as the rate controlling polymer. Methocel K4M was evaluated for its gel forming and 
release controlling properties. Sodium bicarbonate and citric acid were incorporated as gas 
generating agents. The drug release study was evaluated for eight hours using 0.1N HCl. The 
release mechanisms were explored and explained with zero order, first order, Higuchi, Hixon 
Crowell and Korsmeyer equations. It was found that the mean dissolution time, percentage 
drug release, release rate constant and diffusion exponent were influenced significantly by the 
amount of polymer incorporation.  
M Seth et al.,11 designed and characterized of floating tablets of an anti-diabetic drug. The 
objective of the study was to formulate and evaluate floating tablet of Pioglitazone employing 
guar gum, a natural gum in comparison to gellan gum which is also a natural polymer. 
Sodium bicarbonate was added as gas generating agent. Addition of bees wax was 
significantly enhanced the buoyancy of the tablets formulated with both the two polymers. 
The results of in vitro drug release studies showed that optimized formulation could release 
the drug for more than 12 hrs and remain buoyant for 12 hrs. 
CH.Swarna Kamala Chinthala et al.,12 formulated and evaluated gastro retentive floating 
tablets of gabapentin using effervescent technology containing gabapentin in the form of 
tablets using polymers like HPMC K100M, HPMC K15M, Polyox WSR 303 and sodium 
bicarbonate as gas generating agent. At all the strengths of the polymer tested combination of 
HPMC K100M and POLYOX WSR 303 (2:1) gave relatively slow release of gabapentin over 
24 h when compared to other formulations.  The in vitro data is fitted in to different kinetic 
models and the best-fit was achieved with the Higuchi model. The optimized formulation 
followed first order release kinetics followed by non fickian diffusion. 
Sandeep Kumar G et al.,13 formulated and evaluated gastro retentive floating tablets of 
Cefuroxime axetil. The low bioavailability (30-40%) and short biological half-life (1.5 hours) 
of Cefuroxime axetil following oral administration favours development of a gastro retentive 
formulation. Gastro retentive floating matrix tablets of Cefuroxime axetil were successfully 
                                                                                                                2. Review of literature 
 
Department of Pharmaceutics, Madras Medical College.  Page 26 
 
prepared with hydrophilic polymers like HPMC K4M and HPMC K15M. From the 
Preformulation studies for drug excipients compatibility it was observed that there was no 
compatability problem with the excipients used in study. The drug release from most of the 
formulations follows fickian diffusion. From in vivo X-ray studies, it was clearly observed 
that the floating tablets showed a gastric residence of nearby 6 hrs in fed state. 
Prasad K. Lende et al.,14 carried out formulation optimization and in-vitro evaluation of 
floating tablet of Stavudine containing HPMC K100M and Xanthan gum as release retardant 
polymers were studied. Sodium bi-carbonate and citric acid are used as gas generating agents. 
The tablets were prepared by direct compression method. Optimization was done by using 
design expert 8.0.4.1 and optimized formulation of stavudine floating tablet shows no 
significant change in hardness, drug content, floating lag time and % cumulative drug release 
pattern after the stability period of 3 months at 400C/75% relative humidity. 
 
Chandrasekhara Rao Baru et al., 15 formulated and evaluated Ibuprofen floating tablets 
using various polymers like HPMC K4M and Carbopol 940 to enhance the bioavailability and 
therapeutic efficacy of ibuprofen. 4 formulations (F1 to F4) floating tablets of Ibuprofen were 
prepared using variable concentrations of HPMC E5M and Carbopol 940, buoyancy lag time 
and the total floating time was studied for all the formulations, the compatibility evaluations 
were performed by DSC analysis. Studies imply that polymers are compatible with each 
other. There was no interaction found between polymer and drug. 
 
Ravi Kumar et al.,16 formulated and evaluated effervescent floating tablet of Famotidine 
using gas forming agents, like sodium bicarbonate, citric acid and hydrocolloids, like 
hydroxypropyl methylcellulose (HPMC) and carbopol 934P. The formulations were 
optimized for the different viscosity grades of HPMC, carbopol 934P and its concentrations 
and combinations. The results of the in-vitro release studies showed that the optimized 
formulation could sustain drug release (98%) for 24 h and remain buoyant for 24 hrs. The 
optimized formulation was subjected to various kinetic release investigations and it was found 
that the mechanism of drug release was predominantly diffusion with a minor contribution 
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from polymeric relaxation. Optimized formulation showed no significant change in physical 
appearance, drug content, total buoyancy time or in vitro dissolution study after storage at 45 
°C/75% RH for three months. 
Naresh et al.,17 carried out formulation and characterization of effervescent floating tablets of 
Esomeprazole drugs using gas-forming agents, like sodium bicarbonate, citric acid. Floating 
tablets were prepared by wet granulation method using PVP K-30 as a binder and the other 
polymers include HPMC K100M, HPMC K15M and Carbopol 934 P. All the formulations 
showed good floating lag time i.e. less than 3 mins. The batch containing combination of 
HPMC 15M, HPMC K100M and Carbopol 934P showed total floating lag time more than 24 
hrs. The optimized batch showed the highest swelling index among all the prepared batches 
(i.e. 95%). 
Arunachalam A et al.,18 designed and evaluated levofloxacin hemihydrate floating tablets by 
wet granulation method, using the polymer, hydroxypropyl methyl cellulose (HPMC K100M) 
with different amounts and other excipients and sodium bicarbonate as gas generating agent. 
The study aims to improve the oral bioavailability of the drug and to achieve extended 
retention in the stomach which may result in prolonged absorption. 
J. A. Raval et al.,19 formulated Ranitidine hydrochloride floating matrix tablets based on low 
density powder research described an investigation of the effects of formulation and 
processing parameters on a floating matrix controlled drug delivery system consisting of a 
poly (styrene-divinyl benzene) copolymer low density powder. The tablets were prepared 
using hydrophilic matrix polymers HPMC K4M, HPMC K15M, HPMC K100M, sodium 
alginate, psyllum, sesbania gum, guar gum, and gum acacia, with or without low density 
copolymer. The effect of the addition of low density copolymer and the drug release pattern 
were also studied. At the same time, different concentrations of low-density copolymer were 
taken to examine any differences in the floating lag-time of the formulation. The in vitro 
release mechanism was evaluated by kinetic modeling. The tablet eroded/swelled upon 
contact with the release medium, and the relative importance of drug diffusion, polymer 
swelling and tablet erosion on the resulting release patterns varied significantly with the type 
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of matrix forming polymer. The highly porous copolymer provided a low density and, thus, 
excellent in vitro floating behavior of the tablets at a concentration of 15% (w/w). 
Md. Sarfaraz et al.,20 formulated and evaluation bilayer floating tablets of Tramadol 
hydrochloride using release retarding polymers like hydroxypropyl methyl cellulose grades 
(HPMC K4M, K15M, K100M), PEO, Sodium alginate and sodium bicarbonate as gas 
generating agent, with a view to deliver the drug at sustained or controlled manner in 
gastrointestinal tract and consequently in to systemic circulation. Formulations were found 
uniform with respect to thickness (5.04 to 5.07 mm) and hardness (6.3 to 6.6 kg/cm2). The 
friability (0.29 to 0.37%), weight variation (1.44 to 1.71%) and Drug content (98.73 to 
99.23%) of different batch of tablets were found within prescribed limits. Formulation F3 
selected as best formulation, shown buoyancy lag time of 39 sec, total floating time of 36 hrs 
and drug release of 95.90% in a period of 24 hrs. Tablets followed diffusion controlled first 
order kinetics and non-fickian transport of the drug. 
S.Daisy chellakumarai et al.,21 formulated and evaluated floating tablets of Ondansetron 
hydrochloride using various proportions of polymers such as HPMC K4M and Ethyl 
cellulose. This was employed to enhance the bioavailability and therapeutic efficacy of the 
drug. Formulation containing high HPMC K4M and ethyl cellulose showed good floating 
property with total floating time between 8-12 hours. The tablets were also evaluated for its 
hardness, friability and in-vitro evaluation test. All parameters complied with IP limits. 
Results of this study indicated that the combinations of hydrophilic polymers with 
hydrophobic polymers were suitable to optimize sustained release formulation of Ondansetron 
hydrochloride. 
Shailesh S Chalikwar et al.,22 carried out design, development, and in vitro characterization 
of floating-bioadhesive tablets of ciprofloxacin hydrochloride for biphasic release. Biphasic 
tablet formulation consist of, immediate  release layer contained  drug, disintegrant and 
diluent to attain the onset of action quickly and promptly. Floating-bioadhesive sustained 
release layer was prepared by employing 23 factorial designs to study the effect of different 
variables on its properties. Independent variables were selected as concentration of HPMC K 
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4M (X1), concentration of Chitosan (X2) and concentration of effervescent agent (X3) 
whereas % cumulative drug release (Y1), bioadhesive strength (Y2), and floating lag time 
(Y3) were taken as dependent variables. The prepared tablets could float within 3 min and 
remain buoyant for more than 12 hrs. Biphasic release tablet showed satisfactory results with 
profound effect of independent variables on dependent variables, and followed zero order 
kinetics for 12 hrs with non-Fickian diffusion transport with swelling mechanism. 
Priti Tagde et al.,23 Formulated & evaluated bilayer floating tablets of metoprolol tartrate 
using disintegrant starch for the fast release layer and HPMC K grade polymers for the 
sustaining layer. In vitro dissolution studies were carried out in an Indian Pharmacopoeia 
dissolution testing apparatus I (paddle method). The formulations gave an initial burst effect 
to provide the loading dose of the drug followed by sustained release for 12 h from the 
sustaining layer of matrix embedded tablets. The In-vitro release study of this tablet indicated 
sustained release for Metoprolol tartrate and followed zero order release and 95% drug in 
24hrs in vitro and it follow Fickian diffusion. 
Neeraj Kumar Fuloria et al.,24 designed and evaluated gastric floating matrix tablets of an 
anti-hypertensive drug perindropil erbumine by direct compression method. Tablets were 
prepared by using various grades of Hydroxylpropylmethyl cellulose i.e., HPMC K4M, 
HPMC K15M. Sodium bicarbonate and citric acid was incorporated as a gas generating 
agents. The buoyancy lag time was found less than 1 minute for all the prepared tablets and 
affected by viscosity of the polymers and their concentrations. The total floating time for 
different formulations was in the range of 12-14 hrs. The present work concludes that, 
floating tablets of Perindropil Erbumine showed promising result and there exist a scope for 
in vivo evaluation using suitable animal model. 
J Padmavathy et al.,25 Formulated and evaluated ofloxacin floating tablets using HPMC. 
Floating tablets of ofloxacin was shown controlled release thereby proper duration of action at 
a particular site and are designed to prolong the gastric residence time after oral 
administration. Different formulations were formulated by wet granulation technique using 
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HMC K4M, HPMC K15M and HPMC K100M (floating agent) as polymers along with 
sodium bicarbonate as gas generating agent. The formulations were evaluated for their 
physicochemical properties, buoyancy lag time, total floating time, swelling index and in vitro 
drug release.  It was found that the hardness of the tablets affects the buoyancy characteristic 
of the dosage form. All formulation possessed good floating properties with total floating time 
between 8-12 hrs. 
Rajendra Jangde et.al.,26  formulated monolithic floating tablets of Nimesulide. The polymer 
used were HPMC (low & High viscosity), gaur gum, carbopol along with sodium bicarbonate 
as the gas generating agents. The prepared tablets were evaluated their physicochemical 
properties and drug release. In-vitro release studies indicated that the nimesulide release from 
the floating dosage form was uniform & followed zero order release. The incorporation of 
guar gum helps to maintain the devices integrity and due to its viscosity property also affect 
the drugs release profile. Sodium bicarbonate which was used as the gas-generating agents 
causes the tablets to floats the required time>24hrs. 
Krunal patel M et.al.,27 Prepared and evaluated gastro retentive floating tablets of 
mebendazole. The purpose of this research was to prepare a gastro retentive drug delivery 
system of Mebendazole. Chitosan and hydroxypropyl methyl cellulose of various viscosity 
were used. Sodium bicarbonate was incorporated as a gas generating agent. The effects of 
citric acid and stearic acid on drug release profile and floating properties were investigated. 
The addition of stearic acid reduces the drug dissolution due to its hydrophobic nature. The 
specific study was carried out to formulate such a dosage form that can neutralize the acidity 
locally in the stomach. The granulation was formed by fluidized bed processor in which top 
spray technique was adopted for forming the granules. 
Jaimini Manish et al.,28 formulated and evaluated effervescent floating matrix tablet of 
Losartan potassium.  Delayed release tablets of Losartan potassium were formulated using 
two different grades of methocel K100 and K15 by effervescent technique. Sodium 
bicarbonate was employed as gas generating agent. All the prepared tablets showed good in-
vitro buoyancy. A combination of sodium bi carbonate and citric acid was found to achieve 
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optimum in vitro buoyancy. It was observed that tablet remain float for 8-10 hrs. The tablets 
with high grades of methocel (K100) were found to float for longer duration as compared with 
formulations containing methocel K15M. It is evident from this investigation that gas 
powered floating matrix tablet could be promising delivery system for Losartan potassium 
with sustained release action. 
Shweta Sharma et al.,29 formulated captopril floating matrix tablets using different polymers 
as release retarding agent employing various grades of HPMC in varying ratios to formulate 
the floating tablets. Lactose was used as a diluent in the preparation of the tablets. Sodium 
bicarbonate was incorporated into the tablets to aid buoyancy of the tablets. It was concluded 
that the formulation F1 is the best formulations as the extent of drug release was found to be 
around 85%. This batch also showed immediate floatation and floatation duration of more 
than 8hr. The drug release model of this formulation complies with zero order kinetics. 
Roughe N et al.,30 conducted a study to evaluate the factors that improves the in vitro 
buoyancy and drug release profile of floating mini tablets containing either Piretinide or 
Atenolol as the model drug. The buoyancy of the minitablets were achieved either by the 
swelling of the excipients or by incorporating gas generating agent, sodium bicarbonate. The 
study concluded that it was possible to produce mini tablets containing either Piretinide or 
Atenolol, which have a positive resultant weight during more than 6 hrs and satisfactory 
release profiles. 
Ingani HM, et al.,31 described the formulation, dissolution, buoyancy and in vivo release tests 
of a double layer, sustained release Riboflavin phosphate sodium hydrophosphate matrix oral 
tablet containing a carbon dioxide generating layer. The in vivo behavior of this floating tablet 
was then compared to a classical hydrodynamically balanced capsule system. The floating 
dosage forms had increased residence time as compared to the non-floating tablet 
Menon A et al.,32 reported the formulation of a monolithic floating dosage form for 
Furosemide using factorial design keeping the drug to polymer ratio, polymer to polymer ratio 
and polymer grade as the three factors. The optimized formulation thus obtained was found to 
have a good in vitro/in vivo correlation. 
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Shoufeng Li et al.,33 developed an optimized gastric floating drug delivery system for oral 
controlled delivery of Calcium. A central, composite Box-Wilson design for the controlled 
release of calcium was used with three formulation variables; HPMC loading, citric acid 
loading and magnesium stearate loading. All three formulation variables were found to 
significantly affect release properties. Only HPMC loading was found to be significant for 
floating properties. 
Hilton AK, et al.,34 fabricated an oral sustained release floating tablets of Amoxycillin 
trihydrate and carried out the in vitro – in vivo evaluation. From the studies, it shows that the 
drug slowly released in the stomach by diffusion from the floating matrix tablet and then 
trickles towards the proximal intestine where absorption occurs. It improved the delivery of 
antibiotic resulting in more uniform levels of antibiotic following less frequent oral dosing. 
Ozdemir N, et al.,35 developed floating bilayer tablet of Furosemide β-cyclodextrin inclusion 
complex. They determined the gastric residence time using radiographs by adding BaSO4 and 
reported that the tablet stayed in stomach for 6 hrs. Also the bioavailability of Furosemide 
from floating tablet was about 1.8 times those of the conventional tablet and also significant 
in vitro – in vivo correlation was detected. Propranolol in a floating dosage form that 
demonstrates both rapid and sustained release properties were reported. 
Machida S et al.,36 fabricated two drug formulations which floated in gastric juice. One, a 
buoyant tablet, consisted of powdered Soyabean protein, drug and Sodium bicarbonate. The 
other, a laminated film type preparation consisted of a drug film, an effervescing film 
containing Sodium bicarbonate and outer drug release regulating time. Cinnarazine, an acid 
soluble drug was used as the model drug.  
Jimenez-Castellanos et al.,37 designed and tested the in vitro floating and bioadhesive 
property of Sotalol for oral application. Tablets were prepared by mixing the active ingredient 
with Sodium carboxy methyl cellulose, Hydroxy propyl cellulose and a carbonate to generate 
gas. In vitro tests for release of drug, floatation and bioadhesion of the tablets were carried 
out. They concluded that this system showed good characteristics for controlled drug delivery 
system. 
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El-Kamel et al.,38 developed a sustained release system for Ketoprofen to increase its 
residence time in the stomach without contact with the mucosa and was achieved through the 
preparation of floating microparticles by the emulsion solvent diffusion technique. All the 
floating microparticle formulations were evaluated for flow properties, packability and drug 
release rate. 
Joseph NJ, et al.,39 studied the effect of solvent evaporation technique on floating type 
hollow polycarbonate microsphere of Piroxicam which were capable of floating on simulated 
gastric fluid. Pharmacokinetic analysis showed that the bioavailability of Piroxicam hollow 
microsphere was about 1.4 times that of free drug and was about 4.3 times for the dosage 
form consisting of microsphere plus the loading dose. The elimination half-life was increased 
by three times that of free drug.  
Park, et al.,40 developed and evaluated floating beads from Sodium Alginate solution 
containing CaCO3or NaHCO3as gas-forming agents with Riboflavin as a model drug. In vitro 
release studies revealed that CaCO3 is superior to NaHCO3 as gas forming agent in alginate 
bead preparations, with enhanced buoyancy and sustained release properties making them 
excellent for floating drug delivery system. 
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AIM AND PLAN OF WORK 
Aim of project work 
1. The main objective of the present study is to develop gastro retentive floating tablets 
 containing BET hydrochloride as sustained release for the effective treatment of 
 vertigo.  
2. To reduce frequency of administration and improve patient compliance of BET 
 hydrochloride . 
Plan of the work: 
1. Preformulation Studies. 
 Physical compatibility study 
 Chemical compatibility study 
2. Preparation of standard curve for BET hydrochloride. 
3. Precompression studies of blends 
4. Formulation of sustained release granules 
5. Formulation of floating matrix tablets of BET hydrochloride using various grades of 
polymer of HPMC and in different proportions. 
6. Post compression evaluation of tablets 
• Description 
• Uniformity of Weight 
• Hardness 
• Diameter and Thickness 
• Friability 
• Floating characteristics of tablets 
• Swelling index 
• Drug content 
• In vitro release study of tablets 
7. Evaluation of release kinetics of optimized formulation. 
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RATIONALE OF THE STUDY 
 Vertigo is defined as the sensation of motion, when no motion is occurring relative to 
the earth’s gravity. It is a symptom that can be caused by disrupted activity in any part of the 
vestibular system or pathological conditions of other systems. The clinical course of vertigo 
can vary depending on the cause.  Acute, severe attacks of vertigo can last from hours to days.  
 Vertigo is more commonly classified as taking one of three clinical courses; attacks 
lasting seconds or minutes (e.g.vestibular paroxysm), attacks lasting hours (e.g. Meniere’s 
disease or vestibular migraine) or prolonged attacks lasting several days over a week (e.g. 
vestibular neuritis)41,42 
Rationale for selection of drug 
 Betahistine is used to treat vertigo and exerts action by dilating blood vessel within the 
inner ear which can relieve pressure from excess fluid. The successful treatment of vertigo 
depends on the maintenance of effective drug concentration level in the body for which a 
constant and uniform supply of drug is desired.   
 BET hydrochloride is a first line treatment option for otogenic vertigo43. The shorter 
biological half-life (3-4 hours), rapid and complete absorption and the dosage of three times a 
day make BET hydrochloride an ideal candidate for sustained release formulations, which 
reduce the frequency of dose in order to improve patient compliance.43 
Rationale for selection of dosage form 
 The aim of the present study is to formulate gastro retentive matrix tablets using 
various grades of HPMC and in different concentrations.  Hydrophilic polymer matrix 
systems are widely used in oral drug delivery to obtain a desirable drug release profile, cost 
effectiveness, and broad regulatory acceptance. Among the hydrophilic polymers, 
hydroxypropyl methyl cellulose derivatives are frequently used because of their nontoxic 
nature, easy compression, swelling properties and accommodation to high levels of drug 
loading.  
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 Additionally, HPMC is a pH independent material and hence drug release from 
hydroxypropyl methyl cellulose matrix formulations is generally independent of processing 
variables.44 Gastrointestinal resident time of the tablet vary from person to person about 8-12 
hrs.45  Floating drug delivery system is retained in the stomach for prolonged period of time 
and also producing sustained effect. Hence floating technique is employed for the delivery of 
the BET hydrochloride. 
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DISEASE PROFILE 
Vertigo41-42 
      Vertigo is an illusion of movement, where the patient, or the environment, seems to be 
moving. Imbalance always accompanies vertigo, but is not always due to vertigo and is not a 
synonym for vertigo. 
Normal balance requires:  
      (a) Accurate sensory information from the eyes, proprioceptive receptors and the 
vestibular labyrinth (b) Coordination of this information within the brain (c) A normal motor 
output from the central nervous system to an intact musculoskeletal system. A fault in any of 
these impairs balance. 
      Vertigo arises if information from vestibular sources conflicts with that from the other 
sensory systems, or when a disordered central integration system in the brain does not 
correctly assess the body’s movements from vestibular input. Vertigo is always a symptom of 
vestibular defect. This may lie in the peripheral labyrinth or in its connections within the 
brain. When severe it is accompanied by nausea and vomiting. 
Vertigo is caused by:  
(a) Peripheral vestibular disorders (labyrinthine) 
(b) Spread to the labyrinth of infection from middle ear disease  
(c) Central vestibular disorders, such as multiple sclerosis, tumours, infarcts 
(d) External insults to the vestibular system by drugs, anaemia, hypoglycaemia, hypotension,          
viral infection 
The commonest peripheral vestibular disorders are, 
1. Menière’s disease and other forms of endolymphatic hydrops,  
2. Benign paroxysmal positional vertigo,  
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3. Sudden vestibular failure and  
4. Vascular disturbances.41 
Menière’s disease 
      This is a disorder of endolymph control associated with dilatation of the endolymphatic 
spaces of the membranous labyrinth. Dilatation, or endolymphatic hydrops, may be caused by 
disorders of the otic capsule, but in Menière’s disease it is, by definition, idiopathic. The 
disease usually affects only one ear, first producing symptoms between the ages of 30 and 60. 
It is characterised by vertigo, fluctuating hearing loss, tinnitus and sense of pressure in the 
involved ear. Vertigo is of sudden onset, lasts for a few minutes to 24 hours or so. 
Pathology  
 
Fig. 5.1: (A) Normal cochlear duct. (B) Cochlear duct is distended with endolymph pushing 
the Reissner’s membrane into scala vestibuli. 
      The main pathology is distension of endolymphatic system, mainly affecting the cochlear 
duct (scala media) and the saccule, and to a lesser extent the utricle and semicircular canals. 
The dilatation of cochlear duct is such that, it may completely fill the scala vestibuli; there is 
marked bulging of Reissner's membrane which may even herniate through the helicotrema 
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into the apical part of scala tympani. The distended saccule may come to lie against the stapes 
footplate. The utricle and saccule may show out-pouchings into the semicircular canals 
Aetiology 
      The main pathology in Meniere's disease is distension of endolymphatic system due to 
increased volume of endolymph. This can result either from increased production of 
endolymph or its faulty absorption or both. Normally, endolymph is secreted by stria 
vascularis, fills the membranous labyrinth and is absorbed through the endolymphatic sac. 
 
The exact cause of Meniere's disease is not yet known. Various theories have been postulated. 
 
1. Defective absorption by endolymphatic sac  
 
      Normally, endolymph is carried by the endolymphatic duct to the sac where it is absorbed. 
Defective absorption by the sac may be responsible for raised endolymph pressure. 
Experimental obstruction of endolymphatic sac and its duct also produces hydrops. Ischaemia 
of sac has been observed in cases of Meniere's disease undergoing sac surgery, indicating 
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poor vascularity and thus poor absorption by the sac. Distension of membranous labyrinth 
leads to rupture of Reissner's membrane and thus mixing of perilymph with endolymph, 
which is thought to bring about an attack of vertigo.  
2. Vasomotor disturbance  
      There is sympathetic over-activity resulting in spasm of internal auditory artery and/or its 
branches, thus interfering with the function of cochlear or vestibular sensory neuroepithelium. 
This is responsible for deafness and vertigo. Anoxia of capillaries of stria vascularis also 
causes increased permeability, with transudation of fluid and increased production of 
endolymph.  
3. Allergy  
      The offending allergen may be a foodstuff or an inhalant. In these cases, inner ear acts as 
the "shock organ" producing excess of endolymph. Nearly 50% of patients with Meniere's 
disease have concomitant inhalant and/or food allergy.  
It is possible that Meniere's disease is multifactorial, resulting in the common end point of 
endolymphatic hydrops with classical presentation.  
4. Sodium and water retention  
      Excessive amounts of fluid are retained leading to endolymphatic hydrops.  
5. Hypothyroidism  
      About 3% of cases of Meniere's disease are due to hypothyroidism. Such cases benefit 
from thyroid replacement therapy.  
6. Autoimmune and viral aetiologies  
      Have also been suggested on the basis of experimental, laboratory and clinical 
observations.  
 
Treatment of Menière’s disease  
        Medical treatment with vasodilatory drugs such as betahistine may be useful. Nicotinic 
acid in a dose sufficient to cause flushing is an alternative. Menière’s disease might be 
associated with electrolyte imbalance, and so a salt-restricted diet combined with a diuretic is 
often recommended 
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      It has been demonstrated that otoconial debris, consisting of crystals of calcium carbonate, 
is released from the degenerating macula of the utricle and floats freely in the endolymph. 
When it settles on the cupula of posterior semicircular canal in a critical head position, it 
causes displacement of the cupula and vertigo. The vertigo is fatiguable on assuming the same 
position repeatedly due to dispersal of the otoconia but can be induced again after a period of 
rest. Thus, typical history and Hallpike manoeuvre establishes the diagnosis.  
 
      It is characterised by vertigo when the head is placed in a certain critical position. There is 
no hearing loss or other neurologic symptoms. Positional testing establishes the diagnosis and 
helps to differentiate it from positional vertigo of central origin. Disease is caused by a 
disorder of posterior semicircular canal though many patients have history of head trauma and 
ear infection.  
 
 
2. Benign paroxysmal positional vertigo (BPPV)  
Peripheral (Lesions of end organs 
vestibular nerve) 
Central (Lesions of brainstem and central 
connections) 
• Meniere's disease  
• Benign paroxysmal positional 
vertigo  
• Vestibular neuronitis  
• Labyrinthitis  
• Vestibulotoxic drugs  
• Head trauma  
• Perilymph fistula  
• Syphilis  
• Acoustic neuroma  
• Vertebrobasilar insufficiency  
• Posterior inferior cerebellar artery 
syndrome  
• Basilar migraine  
• Cerebellar disease  
• Multiple sclerosis  
• Tumours of brainstem and fourth 
ventricle  
• Epilepsy  
• Cervical vertigo  
                                                                                                                          5. Disease profile 
 
Department of Pharmaceutics, Madras Medical College. Page 42 
 
      The condition can be treated by performing Epley's manoeuvre. The principle of this 
manoeuvre is to reposition the otoconial debris from the posterior semicircular canal back into 
the utricle. The doctor stands behind the patient and the assistant on the side. The patient is 
made to sit on the table so that when he is made to lie down, his head is beyond the edge of 
the table as is done in Dix-Hallpike manoeuvre. His face is turned 45° to the affected side.  
 
      There should be a pause at each position till there is no nystagmus or there is slowing of 
nystagmus, before changing to the next position. After manoeuvre is complete, patient should 
maintain an upright posture for 48 hours. Eighty percent of the patients will be cured by a 
single manoeuvre. If the patient remains symptomatic, the manoeuvre can be repeated. A 
bone vibrator placed on the mastoid bone helps to loosen the debris. 
  
3. Vestibular neuronitis  
      It is characterized by severe vertigo of sudden onset with no cochlear symptoms. Attacks 
may last from a few days to 2 or 3 weeks. It is thought to occur due to a virus that attacks 
vestibular ganglion. Management of acute attack is similar to that in Meniere's disease. The 
disease is usually self-limiting.  
 
4. Labyrinthitis  
      Circumscribed labyrinthitis is seen in cases of unsafe type of CSOM, and fistula test is 
positive.  
      Serous labyrinthitis is caused by trauma or infection (viral or bacterial) adjacent to inner 
ear but without actual invasion. There is severe vertigo and sensorineural hearing loss. A 
partial or full recovery of inner ear functions is possible if treated early.  
 
      Purulent labyrinthitis is a complication of CSOM. There is actual bacterial invasion of 
inner ear with total loss of cochlear and vestibular functions. Vertigo in this condition is due 
to acute vestibular failure. There is severe nausea and vomiting. Nystagmus is seen to the 
opposite side due to destruction of the affected labyrinth.  
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5. Vestibulotoxic drugs  
      Several drugs cause ototoxicity by damaging the hair cells of the inner ear. Some 
primarily affect the cochlear while others affect the vestibular labyrinth. Aminoglycoside 
antibiotics particularly streptomycin, gentamicin, kanamycin have been shown to affect hair 
cells of the crista ampullaris and to some extent those of the maculae. Certain other drugs 
which cause dizziness or unsteadiness are antihypertensives, labyrinthine sedatives, oestrogen 
preparations, diuretics, antimicrobials (nalidixic acid, metronidazole) and antimalarials. 
However, their mode of action may be different. 
  
6. Head trauma  
      Head injury may cause concussion of labyrinth, completely disrupt the bony labyrinth or 
VIIIth nerve, or cause a perilymph fistula. Severe acoustic trauma, such as that caused by an 
explosion can also disturb the vestibular end organ (otoliths) and result in vertigo.  
 
7. Perilymph fistula  
      In this condition, perilymph leaks into the middle ear through the oval or round window. It 
can follow as a complication of stapedectomy, or ear surgery when stapes is accidentally 
dislocated. It can also result from sudden pressure changes in the middle ear (e.g. barotrauma, 
diving, forceful Valsalva) or raised intracranial pressure (weightlifting or vigorous coughing). 
A perilymph fistula causes intermittent vertigo and fluctuating sensorineural hearing loss, 
sometimes with tinnitus and sense of fullness in the ear.  
 
8. Syphilis  
      Syphilis of inner ear, both acquired and congenital, causes dizziness in addition to 
sensorineural hearing loss. Late congenital syphilis usually manifesting between 8 and 20 
years, mimics Meniere's disease with episodes of acute vertigo, sensorineural hearing loss and 
tinnitus. Hennebert's sign, i.e. a positive fistula test in the presence of an intact tympanic 
membrane, is present in congenital syphilis. Neurosyphilis (tertiary acquired) can cause 
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central type of vestibular dysfunction.  
 
9. Acoustic neuroma  
      It has been classified in peripheral vestibular disorders as it arises from CN VIII within 
internal acoustic meatus. It causes only unsteadiness or vague sensation of motion. Severe 
episodic vertigo, as seen in the end organ disease, is usually missing.  
Other tumours of temporal bone (e.g. glomus tumour, carcinoma of external or middle ear and 
secondaries), destroy the labyrinth directly and cause vertigo41.  
 
Duration of vertigo 
• Menière’s disease – hours. 
• Benign paroxysmal positional vertigo – seconds only. 
• Sudden vestibular failure – days 
      Operation is advised if the symptoms are not controlled by medication. Conservative 
surgical procedures aim to protect hearing, and include decompression of the endolymphatic 
sac and selective division of the vestibular branch of the vestibulocochlear nerve (vestibular 
neurectomy). Labyrinthectomy, with total destruction of the membranous labyrinth, 
guarantees relief from the vertigo but at the expense of total loss of hearing in that ear. This is 
often acceptable if the hearing remains only as a painful distorted shred in the affected ear 
when the other is normal. 
Symptomatic treatment of vertigo 
      Symptoms may be relieved by sedatives such as prochlorperazine, cinnarizine and other 
antihistamines. Diazepam is also useful. In a severe attack, bed rest will be necessary 
whatever the cause. Drugs may be given intramuscularly or as suppositories. Once the acute 
stage is over, sedatives are continued in small doses for several weeks or months. 
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If vestibular deficit, rather than irritation of a labyrinthine system, is pronounced, vestibular 
sedatives may exacerbate the symptoms.  
      This often happens in the degenerative changes of old age and in bilateral Menière’s 
disease, or ototoxic damage. Patients can be helped by graded head and eye movement 
exercises, designed to accelerate the process of central compensation. These head exercises 
should be taught and supervised by specially trained physiotherapists. Other treatment is 
directed at identified causes, including surgical exploration of any middle ear in which 
cholesteatomatous erosion of the middle ear is suspected.41,42 
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DRUG PROFILE 
BETAHISTINE HYDROCHLORIDE46-48 
Chemical structure46 
.2HCl 
Chemical name46  
Methyl[2-(pyridin-2-yl)ethyl]amine dihydrochloride. 
CAS number46 
5579-84-0 
Molecular formula46 
C8H12N2.2HCl 
Molecular weight46 
209.11 
Description48 
A white to off white, crystalline powder; sometimes clumped, odourless or almost odourless, 
very hygroscopic. 
Solubility48 
Very soluble in water, soluble in ethanol (95%), practically insoluble in 2-Propanol. 
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Melting point 
150-154 °C 
Category 
Anti-histaminic 
Pharmacology47 
Pharmacokinetics 
Absorption : 
When given orally, betahistine is rapidly absorbed from the gastrointestinal tract. 
Protein binding : 
5% 
Half-life : 
3-4 hours 
Metabolism & elimination:  
Metabolized by liver and excreted through urine (85-90%) 
Mechanism of action47 
Betahistine has a very strong affinity as an antagonist for histamine H3 receptors and a weak 
affinity as an agonist for histamine H1 receptors. Betahistine seems to dilate the blood vessels 
within the inner ear which can relieve pressure from excess fluid and act on the smooth 
muscle. 
Indications47  
Reduction of episodes of vertigo association with Ménière's disease. 
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Dosage46 
Adult    : 16mg tds 
Maintenance  : 24-48 mg daily 
Adverse effects46 
• Headache. 
• Low level of gastric side effects. 
• Insomnia 
• Nausea can be a side effect, but the patient is generally already experiencing nausea 
due to the vertigo so it goes largely unnoticed. 
Contraindications46 
Betahistine should not be given to neonates, children, during pregnancy and lactation and in 
patients with pheochromocytoma. It should be used with caution in patients with asthma or 
peptic ulcer. 
Drug interactions47 
Alcohol 
Storage47 
Store in a well closed container, at room temperature, below 30o C. 
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EXCIPIENTS PROFILE: 
HYPROMELLOSE49 
Nonproprietary Names 
BP: Hypromellose 
JP: Hypromellose 
PhEur: Hypromellose 
USP: Hypromellose 
Synonyms 
Benecel MHPC ; E464; hydroxypropyl methylcellulose; HPMC;hypromellosum; Methocel ; 
methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; Metolose; MHPC; 
Pharmacoat; Tylopur; Tylose MO 
Chemical Name and CAS Registry Number 
Cellulose hydroxypropyl methyl ether [9004-65-3] 
Description  
Hypromellose is an odorless and tasteless, white or creamy-white fibrous or granular powder. 
Functional Category 
Bio adhesive material; coating agent; controlled-release agent; dispersing agent; dissolution 
enhancer; emulsifying agent; emulsion stabilizer; extended-release agent; film-forming agent; 
foaming agent; granulation aid; modified-release agent; mucoadhesive; release-modifying 
agent; solubilizing agent; stabilizing agent; suspending agent; sustained-release agent; tablet 
binder; thickening agent; viscosity-increasing agent. 
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Applications in Pharmaceutical Formulation or Technology  
In oral products, hypromellose is primarily used as a tablet binder, in film-coating, and as a 
matrix for use in extended-release tablet formulations. Concentrations between 2% and 5% 
w/w may be used as a binder in either wet- or dry-granulation processes. High-viscosity 
grades may be used to retard the release of drugs from a matrix at levels of 10–80% w/w in 
tablets and capsules. Hypromellose is also used in liquid oral dosage forms as a suspending 
and/or thickening agent at concentrations ranging from 0.25–5.0%. Depending upon the 
viscosity grade, concentrations of 2–20% w/w are used for film-forming solutions to film-coat 
tablets. Lower-viscosity grades are used in aqueous film-coating solutions, while higher-
viscosity grades are used with organic solvents. Hypromellose is used as an emulsifier, 
suspending agent, and stabilizing agent in topical gels and ointments. As a protective colloid, 
it can prevent droplets and particles from coalescing or agglomerating, thus inhibiting the 
formation of sediments. 
Incompatibilities  
Hypromellose is incompatible with some oxidizing agents. Since it is nonionic, hypromellose 
will not complex with metallic salts or ionic organics to form insoluble precipitates. 
Safety 
Hypromellose is generally regarded as a nontoxic and non-irritating material, although 
excessive oral consumption may have a laxative effect.  
LD50(mouse, IP): 5 g/kg 
LD50(rat, IP): 5.2 g/kg 
Handling Precautions 
Hypromellose dust may be irritating to the eyes, so eye protection is recommended. Excessive 
dust generation should be avoided to minimize the risks of explosion. Hypromellose is 
combustible. 
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MICROCRYSTALLINE CELLULOSE49 
Nonproprietary Names 
BP: Microcrystalline Cellulose 
JP: Microcrystalline Cellulose 
PhEur: Cellulose, Microcrystalline 
USP-NF: Microcrystalline Cellulose 
Synonyms 
Avicel PH; Cellets ; Celex; cellulose gel; hellulosum microcristalli-num; Celphere ; Ceolus 
KG ; crystalline cellulose; E460; Emcocel; Ethispheres ; Fibrocel; MCC Sanaq; Pharmacel; 
Tabulose ; Vivapur. 
Chemical Name and CAS Registry Number 
Cellulose [9004-34-6] 
Empirical Formula and Molecular Weight 
(C6H 10O5)n  36 000 
where n  220. 
Functional Category 
Adsorbent; suspending agent; tablet and capsule diluent; tablet disintegrant.  
Description 
Microcrystalline cellulose is a white, odorless, tasteless, crystalline powder composed of 
porous particles.  
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Use Concentration(%) 
Adsorbent 20-90 
Antiadherent 5-20 
Capsule binder/diluent 20-90 
Tablet disintegrant 5-15 
Tablet binder/diluent 20-90 
 
Stability and Storage Conditions 
Microcrystalline cellulose is a stable though hygroscopic material. The bulk material should 
be stored in a well-closed container in a cool, dry place. 
Incompatibilities 
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
Safety 
Microcrystalline cellulose is not absorbed systemically following oral administration and thus 
has little toxic potential. Consumption of large quantities of cellulose may have a laxative 
effect. Deliberate abuse of formulations containing cellulose, either by inhalation or by 
injection, has resulted in the formation of cellulose granulomas. 
Handling Precautions 
Microcrystalline cellulose may be irritant to the eyes. Gloves, eye protection, and a dust mask 
are recommended. In the UK, the workplace exposure limits for cellulose have been set at 10 
mg/m3 long-term (8-hour TWA) for total inhalable dust and 4 mg/m3 for respirable dust; the 
short-term limit for total inhalable dust has been set at 20 mg/m3. 
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SODIUM BICARBONATE49 
Nonproprietary Names 
BP: Sodium bicarbonate 
JP: Sodium bicarbonate 
PhEur: Natrii hydrogenocarbonas 
USP: Sodium bicarbonate 
Synonyms 
Baking soda; E500; Effer-Soda; monosodium carbonate; Sal de Vichy; sodium acid 
carbonate; sodium hydrogen carbonate. 
Chemical Name and CAS Registry Number 
Carbonic acid monosodium salt [144-55-8] 
Empirical Formula and Molecular Weight 
NaHCO3-84.01 
Functional Category 
Alkalizing agent 
Applications in Pharmaceutical Formulation or Technology 
Sodium bicarbonate is generally used in pharmaceutical formulations as a source of carbon 
dioxide in effervescent tablets and granules. It is also widely used to produce or maintain an 
alkaline pH in a preparation. 
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Use Concentration (%) 
Buffer in tablets 10-40 
effervescence 25-50 
Isotonic injection/infusion 1.39 
 
Description 
Sodium bicarbonate occurs as an odorless, white, crystalline powder with a saline, slightly 
alkaline taste.  
Incompatibilities 
Sodium bicarbonate intensifies the darkening of salicylates. In solution, sodium bicarbonate 
has been reported to be incompatible with many drug substances such as ciprofloxacin, 
amiodarone, nicardipine, and levofloxacin. 
Safety 
Sodium bicarbonate is metabolized to the sodium cation, which is eliminated from the body 
by renal excretion, and the bicarbonate anion, which becomes part of the body’s bicarbonate 
store. Any carbon dioxide formed is eliminated via the lungs. Administration of excessive 
amounts of sodium bicarbonate may thus disturb the body’s electrolyte balance, leading to 
metabolic alkalosis or possibly sodium overload with potentially serious consequences.  
LD50 (mouse, oral): 3.36 g/kg 
LD 50 (rat, oral): 4.22 g/kg 
Handling Precautions 
Eye protection and gloves are recommended. 
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POVIDONE K3049 
Nonproprietary Names 
BP: Povidone 
JP: Povidone 
PhEur: Povidonum 
USP: Povidone 
Synonyms 
E1201;Kollidon ; Plasdone ; poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; polyvidone; 
polyvinylpyrrolidone; PVP; 1-vinyl-2-pyrrolidinone polymer. 
Chemical Name and CAS Registry Number 
1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8] 
Empirical Formula and Molecular Weight 
(C6 H 9NO) n 2500–3 000 000 
Approximate molecular weight for different grades of povidone. 
K-value Approximate molecular weight 
12 2 500 
15 8 000 
17 10 000 
25 30 000 
30 50 000 
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60 400 000 
90 1 000 000 
120 3 000 000 
 
Functional Category 
Disintegrant; dissolution aid; suspending agent; tablet binder. 
Applications in Pharmaceutical Formulation or Technology 
In tableting, povidone solutions are used as binders in wet granulation processes. Povidone is 
also added to powder blends in the dry form and granulated in situ by the addition of water, 
alcohol, or hydroalcoholic solutions. Povidone is used as a solubilizer in oral and parenteral 
formulations and has been shown to enhance dissolution of poorly soluble drugs from solid-
dosage forms. Povidone solutions may also be used as coating agents 
Uses of povidone. 
Use Concentration (%) 
Carrier for drugs 10–25 
Dispersing agent  Up to 5 
Eye drops 2–10 
Suspending agent Up to 5 
Tablet binder, tablet diluent, or coating agent 0.5-5 
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Description 
Povidone occurs as a fine, white to creamy-white colored, odorless or almost odorless, 
hygroscopic powder. 
Stability and Storage Conditions 
Aqueous solutions are susceptible to mold growth and consequently require the addition of 
suitable preservatives. Povidone may be stored under ordinary conditions without undergoing 
decomposition or degradation.  However, since the powder is hygroscopic, it should be stored 
in an airtight container in a cool, dry place. 
Incompatibilities 
It forms molecular adducts in solution with sulfathiazole, sodium salicylate, salicylic acid, 
phenobarbital, tannin, and other compounds; The efficacy of some preservatives, e.g. 
thiomersal, may be adversely affected by the formation of complexes with povidone. 
Safety 
Povidone may be regarded as essentially nontoxic since it is not absorbed from the 
gastrointestinal tract or mucous membranes. Povidone additionally has no irritant effect on the 
skin and causes no sensitization.  Reports of adverse reactions to povidone primarily concern 
the formation of subcutaneous granulomas at the injection site of intramuscular injections 
formulated with povidone. A temporary acceptable daily intake for povidone has been set by 
the WHO at up to 25 mg/kg body-weight. 
LD50 (mouse, IP): 12 g/kg 
Handling Precautions 
Eye protection, gloves, and a dust mask are recommended. 
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ISOPROPYL ALCOHOL49 
Nonproprietary Names 
BP: Isopropyl alcohol 
JP: Isopropanol 
PhEur: Alcohol isopropylicus 
USP: Isopropyl alcohol 
Synonyms 
Dimethyl carbinol; IPA; isopropanol; petrohol; 2-propanol; sec- propyl alcohol. 
Chemical Name and CAS Registry Number 
Propan-2-ol [67-63-0] 
Empirical Formula and Molecular Weight 
C3 H8O - 60.1 
Functional Category 
Disinfectant; solvent. 
Applications in Pharmaceutical Formulation or Technology 
Isopropyl alcohol (propan-2-ol) is used in cosmetics and pharmaceutical formulations 
primarily as a solvent in topical formulations. Although it is used in lotions, the marked 
degreasing properties of isopropyl alcohol may limit its usefulness in preparations used 
repeatedly. Isopropyl alcohol is also used as a solvent both for tablet film-coating and for 
tablet granulation, where the isopropyl alcohol is subsequently removed by evaporation.  It 
has also been shown to significantly increase the skin permeability of nimesulide from 
carbomer 934.  Isopropyl alcohol has some antimicrobial activity and a 70% v/v aqueous 
solution is used as a topical disinfectant. 
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Description 
Isopropyl alcohol is a clear, colorless, mobile, volatile, flammable liquid with a characteristic, 
spirituous odor resembling that of a mixture of ethanol and acetone; it has a slightly bitter 
taste. 
Solubility:  
Miscible with benzene, chloroform, ethanol (95%), ether, glycerin, and water. Soluble in 
acetone; insoluble in salt solutions. Forms an azeotrope with water, containing 87.4% w/w 
isopropyl alcohol (boiling point 80.37 8 C). 
Stability and Storage Conditions 
Isopropyl alcohol should be stored in an airtight container in a cool, dry place. 
Incompatibilities 
Incompatible with oxidizing agents such as hydrogen peroxide and nitric acid, which cause 
decomposition. Isopropyl alcohol may be salted out from aqueous mixtures by the addition of 
sodium chloride, sodium sulfate, and other salts, or by the addition of sodium hydroxide. 
Safety 
It is readily absorbed from the gastrointestinal tract and may be slowly absorbed through 
intact skin. Prolonged direct exposure of isopropyl alcohol to the skin may result in cardiac 
and neurological deficits. In neonates, isopropyl alcohol has been reported to cause chemical 
burns following topical application.  Isopropyl alcohol is metabolized more slowly than 
ethanol, primarily to acetone. The lethal oral dose is estimated to be about 120–250 mL 
although toxic symptoms may be produced by 20 mL. 
Handling Precautions 
Isopropyl alcohol may be irritant to the skin, eyes, and mucous membranes upon inhalation. 
Eye protection and gloves are recommended.  Isopropyl alcohol should be handled in a well-
ventilated environment. 
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MATERIALS AND METHODS 
The list of drug and excipients, their manufacturers and use in the present study are shown in 
Table 8.1 
Tab. 8.1: List of materials and their applications in formulation 
S.No Name of material Manufacturer / supplier Use in formulation 
1 Betahistine hydrochloride Madras Pharmaceutical  
( P) Ltd 
Active ingredient 
2 HPMC K4M 
 
Shandong Head Co., Ltd Hydrophilic polymer 
3 HPMC K100M 
 
Shandong Head Co., Ltd Hydrophilic polymer 
4 Micro crystalline 
cellulose 
Amit cellulose Diluent  
5 Sodium bicarbonate 
 
Indian research products Gas generating agent 
6 PVP K30 
 
Jiao Zuo yuanhai fine 
Chemicals Ltd., 
Binding agent 
7 Magnesium stearate 
 
Zudila enterprise Lubricant  
8 Isopropyl alcohol 
 
Microfine chemicals Solvent 
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The list of instruments/equipments used in the present study and their manufacturer are shown 
in Table 8.2 
Tab. 8.2: List of equipment used 
 
 
 
 
 
S.NO Equipment / instruments Manufacturer /supplier 
1 Electronic weighing balance 
 
Shimadzu, Japan 
2 Hot air oven 
 
MC Dalal, Chennai 
3 10 Station compression machine 
 
Rimek, India 
4 Vernier caliper 
 
Mitutoyo, Japan 
5 Monsanto hardness tester 
 
Erweka, Mumbai 
6 Friabilator 
 
Electrolab, India 
7 Dissolution tester 
 
Veego, India 
8 UV-visible spectrophotometer 
 
Shimadzu, Japan 
9 Fourier transform infrared spectrophotometer 
 
Nicolet, India 
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METHODOLOGY 
Preformulation studies 
 The Preformulation studies are conducted to establish the physiochemical 
characteristics of the drug and its compatibility with the various excipients. The 
Preformulation studies are necessary to formulate drug into stable, safe and effective dosage 
form. 
Drug-excipient compatibility study 
 The drug and excipients selected for the formulation are evaluated for physical and 
chemical compatibility studies. 
Physical compatibility study 
 The physical compatibility studies are conducted to provide valuable information to 
the formulator in selecting the appropriate excipients for the formulation. It was done by 
mixing the drug and excipients and kept at room temperature and at 40°C and 75%RH. Any 
color change of the physical mixture was observed visually.50 
Chemical compatibility study 
 Pure drug, polymers, excipients and drug-excipient mixture were subjected to FTIR to 
investigate the drug-excipient interactions. The IR spectra of test samples were obtained using 
potassium bromide pellet method.51 
Preparation of 0.1 N HCl 
 8.5 mL of hydrochloric acid was mixed with about 600 ml of distilled water and the 
volume was made up to 1000 ml with distilled water.52 
Calibration curve  
 100mg of BET hydrochloride was weighed and transferred into 100 mL standard flask 
and made up to 100 ml with 0.1 N HCl. From the above solution 10 mL was taken and made 
up to 100 mL using 0.1N HCL. From the above solution 2 mL, 4 mL, 6 mL, 8 mL and 10 mL 
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were taken and made up to 100mL using 0.1N HCL. The absorbance of the resulting solutions 
was measured at 261 nm53 using UV spectrophotometer. Calibration curve was plotted taking 
concentration on X axis and absorbance on Y axis. 
Pre formulation studies of the blends54 
 The flow property measurements include bulk density, tapped density, angle of repose, 
compressibility index and Hausner’s ratio. The flow property measurements of drugs and 
blends are determined. 
I. Bulk density 
Bulk density is the ratio of weight of powder to bulk volume. A sample of 10g of 
powder was carefully introduced into measuring cylinder with the aid of funnel and 
volume occupied by the powder was noted. Bulk density is expressed in g/ml. 
                                            M 
                  Bulk density=   
                                            Vb 
Where, 
             M = weight of sample in grams 
             Vb=bulk volume 
 
II. Tapped density 
Tapped density is the ratio of weight of powder to tapped volume of powder. The 10g 
of powder was introduced into the measuring cylinder with the aid of funnel and 
tapped from the height of 1 inch for 500 times on a hard wooden surface at 2 seconds 
interval and the volume obtained was noted. Tapped density is expressed in g/ml. 
                                             M 
               Tapped density=      
                                             Vt 
Where, 
            M = weight of sample in grams 
            Vt= tapped volume 
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III. Angle of repose 
Angle of repose measures the frictional force involved in the powder. It is defined as 
the maximum angle possible between the surface of a pile of powder and the 
horizontal plane. It is determined by fixed funnel method. The powder mixture 
allowed to flow through the funnel fixed to a stand at define height. The angle of 
repose is then calculated by the formula  
                         θ= tan-1(h/r) 
where, 
           θ= angle of repose in degrees 
           h= height of the pile of powder in cm 
           r= radius of pile of powder in cm 
 
Tab. 8.3: Values of angle of repose, compressibility index, Hausner’s ratio 
 
Flow property Angle of repose (in 
degrees) 
Compressibility 
index (%) 
Hausner’s ratio 
Excellent  25-30 <10 1.00-1.11 
Good 31-35 11-15 1.12-1.18 
Fair  36-40 16-20 1.19-1.25 
Passable  41-45 21-25 1.26-1.34 
Poor 46-55 26-31 1.35-1.45 
Very poor 56-65 32-37 1.46-1.59 
Very very poor >65 >38 >1.60 
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IV. Compressibility index or Carr’s index 
Compressibility index is the measure of flow property of a powder. It is measured for 
determining the relative importance of inter particulate interactions. It is expressed in 
percentage and calculated by formula mentioned below. 
                                                      Tapped density-bulk density 
          Compressibility index=         x 100                                                                                                                        
                                                            Tapped density     
V. Hausner’s ratio 
Hausner’s ratio is the measure of propensity of powder to be compressed and also 
inter particulate interactions. Hausner’s ratio is calculated by the formula mentioned 
below. 
                                         Tapped density 
          Hausner’s ratio=    
                                           Bulk density 
Formulation of sustained release BET hydrochloride floating tablets 
 The sustained release tablets of BET hydrochloride were prepared by wet granulation 
technique. Different grades of HPMC polymer such as HPMC K4M and HPMC K100M were 
used alone and in different ratios. All the ingredients except magnesium stearate were sieved 
through mesh no. 22 and transferred to a clean porcelain mortar. PVP (5% w/w) binding 
solution was added to the powder mixture in small quantities, while mixing thoroughly after 
each addition until a coherent mass was formed. Then it was passed through sieve no.10 and 
the wet granules were dried in hot air oven at 60oC for 30 min. The dried granules were 
lubricated with magnesium stearate and compressed into tablet using 10 station tablet 
compression machine. 
 
 
 
 
                                                                                                           8. Materials and methods 
 
Department of Pharmaceutics, Madras Medical College. Page 66 
 
Tab. 8.4: Formulation of Floating tablets 
Ingredients F-I F-II F-III F-IV F-V F-VI F-VII F-VIII F-IX 
Betahistine 
hydrochloride 
24 24 24 24 24 24 24 24 24 
HPMC K4M 120 150 180 - - - 30 60 90 
HPMCK100M - - - 120 150 180 90 90 90 
Microcrystalline 
cellulose 
85 55 25 85 55 25 85 55 25 
Sodium 
bicarbonate 
50 50 50 50 50 50 50 50 50 
PVP K30 15 15 15 15 15 15 15 15 15 
Magnesium 
stearate 
6 6 6 6 6 6 6 6 6 
Isopropyl alcohol 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 
Average weight of one tablet = 300 mg 
Tab. 8.5:  % of polymers used in formulation of BET hydrochloride floating tablets 
 
Formulation 
% of Polymer used 
HPMC K4M HPMC K100M 
F-I 40 - 
F-II 50 - 
F-III 60 - 
F-IV - 40 
F-V - 50 
F-VI - 60 
F-VII 10 30 
F-VIII 20 30 
F-IX 30 30 
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Fig.8.1: Schematic representation of formulation development of BET hydrochloride 
floating tablets 
 
 
 
  
  
Betahistine 
hydrochloride 
HPMC K4M 
HPMC K100M 
Microcrystalline 
cellulose 
Sodium bicarbonate 
PVP K30 
Magnesium stearate 
Dispensing
gng  
sifting 
Blended with excipients except IPA, 
PVP K30 and Magnesium stearate 
Precompression study 
Wetted with PVP K30 solution 
Granules were dried and lubricated with 
Magnesium stearate 
Compression  
Sustained release floating tablets Post compression study 
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Evaluation of Tablets: 
Description:55 
Ten tablets were selected randomly and placed in a petridish. The tablets were 
observed from both the sides for colour, shape and appearance. 
Uniformity of Weight: 56 
Twenty tablets were selected at random from each batch. The individual tablet was 
weighed and the average weight was determined. The individual weight was compared with 
the average weight. Not more than two of the individual weights deviate from the average 
weight by more than the percentage shown in the table 8.6 and none deviates by more than 
twice that percentage. 
Tab. 8.6: Uniformity of Weight 
S.No Average weight of a tablet % Deviation 
1. 80 mg or less 10 
2. More than 80 mg but less than 250 
mg 
7.5 
3. 250 mg or more 5 
 
Diameter and thickness: 57 
Diameter and thickness of tablets were determined using vernier Caliper. Five tablets 
from each batch were used and average value was calculated. 
Hardness: 57 
The crushing strength of the tablets were measured using a Monsanto Hardness tester. 
Five tablets from each batch were tested randomly and the average was recorded. 
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Friability: 58 
Tablets of weight equivalent to 6.5 g were weighed and placed in a Roche Friabilator. 
The equipment was rotated at a speed of 25 rpm for 4 minutes. The tablets were taken out, 
dedusted and reweighed. The percentage friability of the tablets was measured as per the 
following formula: 
F = (1-W/W0) X 100 
Where  
W is the weight of the tablets after the test 
W0 is the weight of the tablets before the test 
Drug Content: 57 
10 tablets were weighed and powdered. The average weight was determined. The 
powder equivalent to 24 mg of drug was weighed and transferred to a 100 mL volumetric 
flask. It was then made up to volume with 0.1 N HCl. 10 mL was pipetted out into a 100 ml 
standard flask and made up to volume with  0.1 N HCl.  The absorbance of the resulting 
solution was measured at 261 nm using UV-Visible Spectrophotometer taking 0.1 N HCl as 
blank. The content of BET hydrochloride was then calculated.  
In vitro floating studies:57 
 Floating time was determined using USP dissolution apparatus-II, 900 mL of 0.1N 
HCl and temperature was maintained at 37±0.50C. The duration of floating and floating lag 
time, were measured by visual observation.  
Determination of Swelling Index:57 
 The swelling index of tablets was determined in 0.1N HCl (pH 1.2) at room 
temperature. The swollen weight of the tablet was determined at predefined time intervals 
                                                                                                           8. Materials and methods 
 
Department of Pharmaceutics, Madras Medical College. Page 70 
 
over a period of 24 h. The swelling index (SI), expressed as a percentage, was calculated from 
the following equation. 
 SI =         Weight of tablet at time (t) - Initial weight of tablet/Initial weight of tablet 
In vitro release study of the tablets: 57 
In vitro dissolution studies were carried out using USP dissolution test apparatus-II, 
employing a paddle at 50 rpm using 900 mL of 0.1 N HCl at 37±0.50C as dissolution medium. 
One tablet was used in each test. At predetermined time intervals 10 mL of the samples were 
withdrawn by means of a pipette. The medium withdrawn at each interval was replaced with 
the same quantity of fresh dissolution medium. The samples were analyzed for drug release 
by measuring the absorbance at 261 nm using UV-Visible spectrophotometer. All the studies 
were conducted in triplicate.   
RELEASE KINETICS OF THE OPTIMIZED FORMULATION:59 
To study the kinetics, data obtained from in vitro release were plotted in various 
kinetics models. 
1. Zero order release model: 
Zero order models describe the systems where the drug release rate is independent of its 
concentration. 
C = K₀ t 
Where 
C – Cumulative percentage of drug released 
K₀ - Zero-order constant 
t – Time 
A plot of time on x-axis and cumulative percentage of drug released on y-axis gives a straight 
line with slope (k₀) if it follows zero order kinetics. 
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2. First order release model: 
First order models describe the systems where the release rate is dependent on the 
concentration. 
Log C = log C₀ - K t/2.303 
Where 
C – Cumulative percentage of drug remaining 
C0 - Initial concentration of drug 
k – First order constant 
A plot of time on x-axis and log cumulative percentage of drug remaining on y-axis gives a 
straight line with slope (k/2.303) if it follows first order kinetics. 
3. Higuchi release model: 
The Higuchi model describes the release from systems where the solid drug is dispersed in an 
insoluble matrix and the rate of release is related to the rate of drug diffusion. 
Q = kt1/2  
Where 
Q – Cumulative percentage of drug released 
k – Constant reflecting the design variables of the system 
t – Time 
A plot of square root of time on x-axis and cumulative percentage drug released on y-axis 
gives a straight line if it follows Higuchi kinetics. 
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4. Hixson-Crowell release model: 
The Hixson-Crowell cube root model describes the release from systems where there is a 
change in surface area and diameter of the tablets or particles. 
Q01/3 – Qt1/3 = KHC t  
Where 
Qt – Cumulative percentage drug released in time t 
Q0 – initial amount of drug 
KHC – Rate constant for Hixson-Crowell rate equation 
    t – Time  
A plot of time on x-axis and cube root of cumulative percentage of drug remaining on y-axis 
gives a straight line if it follows Hixson-Crowell kinetics. 
5. Korsemeyer-Peppas model: 
Korsemeyer-Peppas model derived a simple relationship which describes the drug release 
from a polymeric system. 
Mt/M∞ = Ktn  
Where 
Mt/M∞ - Fraction of drug released at time t 
k – Release rate constant 
n – Release exponent 
A plot of log time on x-axis and log cumulative percentage of drug released on y-axis gives a 
straight line if it follows Korsemeyer-Peppas kinetics. The n value is used to characterize 
different release mechanism. 
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Tab. 8.7: Diffusion exponent and solute release mechanism for cylindrical shape 
Diffusion 
exponent (n) 
Overall solute diffusion 
mechanism 
0.45 Fickian diffusion 
0.45 < n <0.89 Anomalous (non-Fickian) 
diffusion 
0.89 Case-II transport 
n > 0.89 Super case-II transport 
 
In vitro drug release data were fitted to various models such as zero order, first order, 
Higuchi equation, Korsmeyer-Peppas equation, and Hixson-Crowell equation to know about 
the mechanism of drug release. 
Stability studies  
 Short term stability studies were performed at a temperature of 40±20C and RH of 
75±5% over a period of three months on the promising formulation. Sufficient number of 
tablets (20) were packed in amber colored screw capped bottles and kept in stability chamber 
maintained at 40±20C and RH 75±5%. Samples were taken at monthly intervals and tested for 
physical properties, drug content and in vitro drug release. 
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RESULTS AND DISCUSSION 
Physical compatibility study: 
The drug and the excipients were tested for their physical compatibility in order to obtain a 
safe and efficient dosage form. The results of the compatibility study are listed in Table 9.1 
Tab. 9.1: Physical Compatibility study of drug and excipients 
The physical compatibility study was performed and the results showed that there was no sign 
of incompatibility. The drug and the excipients are physically compatible. 
S.No Drug and Excipients Descriptions and conditions 
Initial Room 
temperature 
40±2oC 
days 
10 20  30 10 20 30 
1. BET hydrochloride Off-white coloured 
powder 
NC NC NC NC NC NC 
2. HPMC  White coloured powder NC NC NC NC NC NC 
3. BET+HPMC K4M white coloured powder NC NC NC NC NC NC 
4. BET+HPMC K100M White coloured powder NC NC NC NC NC NC 
5. BET + MCC white coloured powder NC NC NC NC NC NC 
6. BET + Sodium 
bicarbonate 
White coloured powder NC NC NC NC NC NC 
7. BET + PVP K 30 Pale yellow coloured 
powder 
NC NC NC NC NC NC 
8. BET + Magnesium 
stearate 
White coloured powder NC NC NC NC NC NC 
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FTIR Study – Identification and Compatibility of Drug and Polymer: 
The identification of drug and the compatibility between the drug and polymers was 
carried out using FTIR. The FTIR spectra of the pure drug, drug polymer mixtures and tablet 
powder are shown in Figures 9.1 to 9.7 and interpretation are shown in table 9.2 to 9.8 
Fig. 9.1: FTIR Spectrum of Betahistine hydrochloride 
 
Tab. 9.2: FTIR Spectrum of BET HCl 
Wave Number (cm-1) Interpretation 
3417 N-H Stretching 
2923 C-H Stretching (aliphatic) 
1620 C=C Stretching 
1485 C-N Stretching 
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Fig. 9.2: FTIR Spectrum of BET hydrochloride and HPMC K4M 
 
Table 9.3: FTIR Spectrum of BET HCl and HPMC K4M 
Wave Number (cm-1) Interpretation 
3433 N-H Stretching 
2931 C-H Stretching (aliphatic) 
1643 C=C Stretching 
1458 C-N Stretching 
 
The peaks observed in the FTIR spectrum of BET HCl with HPMC K4M showed no 
shift and no disappearance of characteristic peaks of drug. This suggests that there is no 
interaction between the drug and HPMC K4M. 
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Fig. 9.3: FTIR Spectrum of BET HCl and HPMC K100M 
 
Tab. 9.4: FTIR Spectrum of BET HCl and HPMC K100M 
Wave Number (cm-1) Interpretation 
3448 N-H Stretching 
2931 C-H Stretching (aliphatic) 
1635 C=C Stretching 
1485 C-N Stretching 
 
The peaks observed in the FTIR spectrum of BET HCl with HPMC K100M showed 
no shift and no disappearance of characteristic peaks of drug. This suggests that there is no 
interaction between the drug and HPMC K100M. 
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Fig. 9.4:FTIR Spectrum of BET and Sodium bicarbonate 
 
Tab. 9.5: FTIR Spectrum of BET and Sodium bicarbonate 
Wave Number (cm-1) Interpretation 
3433 N-H Stretching 
3008 C-H Stretching (aliphatic) 
1627 C=C Stretching 
1473 C-N Stretching 
 
The peaks observed in the FTIR spectrum of BET HCl with Sodium bicarbonate 
showed no shift and no disappearance of characteristic peaks of drug. This suggests that there 
is no interaction between the drug and Sodium bicarbonate. 
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Fig. 9.5: FTIR Spectrum of BET HCl and PVP K30 
 
Tab. 9.6: FTIR Spectrum of BET HCl and PVP K30 
Wave Number (cm-1) Interpretation 
3425 N-H Stretching 
2954 C-H Stretching (aliphatic) 
1658 C=C Stretching 
1485 C-N Stretching 
 
 The peaks observed in the FTIR spectrum of BET HCl with PVP K30 showed no shift 
and no disappearance of characteristic peaks of drug. This suggests that there is no interaction 
between the drug and PVP K30. 
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Fig. 9.6: FTIR Spectrum of BET HCl and MCC 
 
Tab.9.7: FTIR Spectrum of BET HCl and MCC 
Wave Number (cm-1) Interpretation 
3394 N-H Stretching 
2900 C-H Stretching (aliphatic) 
1627 C=C Stretching 
1427 C-N Stretching 
 
 The peaks observed in the FTIR spectrum of BET HCl with MCC showed no shift and 
no disappearance of characteristic peaks of drug. This suggests that there is no interaction 
between the drug and MCC. 
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Fig 9.7: FTIR Spectrum of BET HCl and Magnesium stearate 
 
Tab. 9.8: FTIR Spectum of BET HCl and Magnesium stearate 
Wave Number (cm-1) Interpretation 
3409 N-H Stretching 
2916 C-H Stretching (aliphatic) 
1697 C=C Stretching 
1465 C-N Stretching 
  
 The peaks observed in the FTIR spectrum of BET HCl with Magnesium stearate 
showed no shift and no disappearance of characteristic peaks of drug. This suggests that there 
is no interaction between the drug and Magnesium stearate. 
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Standard Curve of Betahistine hydrochloride: 
The absorbance of the drug in different concentrations in 0.1N Hydrochloric acid was 
measured at a wavelength of 261 nm. The results are given in Table 9.9. The standard curves 
plotted using the absorbance of various concentrations is shown in Figure 9.8 
Tab. 9.9: Data for Standard curve of BET HCl 
S.No Concentration 
(μg/ml) 
Absorbance at 261 nm 
1. 0 0 
2. 2 0.075 
3. 4 0.150 
4. 6 0.229 
5. 8 0.313 
6. 10 0.390 
 
Fig. 9.8: Standard Curve of BET hydrochloride in 0.1N HCl 
 
  The standard curve is linear and starts from the origin. It obeys Beer – Lambert’s law. 
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Precompression studies of the drug and powder blends:  
The results of the precompression study of the powder blends are given in Table 9.10 and 
Figures 9.9 to 9.13 
.Tab.9.10: Precompression study of powder blends 
Drug/ 
Powder 
blends 
Bulk density* 
(g/cm3) 
Tapped 
density* 
(g/cm3) 
Compressibility 
index* (%) 
Hausner’s 
ratio* 
Angle of 
Repose* (θ) 
F-I 0.4000±0.047 0.5263±0.015 23.99±0.024 1.32±0.017 30003’  ±0.054 
F-II 0.4167±0.055 0.5556±0.032    25.00±0.038 1.33±0.009 31036’±0.026 
F-III 0.3846±0.023 0.5000±0.067 23.08±0.016 1.30±0.025 32069’±0.054 
F-IV 0.4000±0.041 0.5263±0.052 23.99±0.037 1.31±0.052 31098’±0.035 
F-V    0.4081±0.016 0.5128±0.043 20.41±0.021 1.25±0.038 32060’±0.062 
F-VI 0.4347±0.047 0.5556±0.068 21.76±0.059 1.27±0.027 30007’±0.028 
F-VII 0.3778.±0.038 0.5000±0.016 24.44±0.028 1.32±0.045 31002’±0.063 
F-VIII 0.4000±0.054 0.5263±0.047 23.99±0.015 1.32±0.029 31008’±0.037 
F-IX 0.4081±0.019 0.5128±0.035 20.41±0.012 1.26±0.053 32021’±0.046 
 
The drug blend has passable flow property. Hence, the tablets were prepared by wet 
granulation technique. 
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Fig. 9.9: Bulk density of powder blend 
 
 The bulk density of the powder blend of various formulations ranged from 0.3846 g/cm3 to 
0.4347 g/cm3. 
Fig. 9.10: Tapped density of powder blend 
 
The tapped density of various formulations ranged from 0.5000 g/cm3 to 0.5556 g/cm3  
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Fig. 9.11: Compressibility Index of powder blend 
 
The compressibility index of various formulations ranged from 20.41% to 25.00% showing 
passable flow property. Hence wet granulation was used. 
 
Fig. 9.12: Hausner’s ratio of powder blend 
 
The Hausner’s ratio of various formulations ranged from 1.26 to 1.33 showing passable flow 
property. 
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Fig. 9.13: Angle of repose of powder blend 
 
The angle of repose of various formulations ranged from 30⁰03’ to 32⁰69’ showing good 
flow property. 
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Evaluation of floating tablets: 
1. Description: 
The tablets were white coloured, round and flat faced with bevel – edged bisect.   
2. Uniformity of Weight: 
The tablets were tested for uniformity of weight and the results are given in Table 9.11 
Tab.9.11: Uniformity of Weight of floating tablets 
 
    *Mean±SD (n=3) 
The weight of the tablets ranged from 0.2952 g to 0.3040 g. The tablets (F-I to F-IX) comply 
with the uniformity of weight test.56 
Formulation Average Weight* (g) 
F-I 0.3023±0.0015 
F-II 0.3024±0.0053 
F-III 0.3022±0.0026 
F-IV 0.3034±0.0032 
F-V 0.3040±0.0021 
F-VI 0.3025±0.0039 
F-VII 0.3017±0.0044 
F-VIII 0.2952±0.0037 
F-IX 0.2995±0.0018 
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3. Thickness: 
Thickness of various formulations is given in Table 9.12. 
Tab. 9.12: Thickness of floating tablets 
Formulation Thickness* (mm) 
F-I 4.0±0.012 
F-II 4.0±0.015 
F-III 4.0±0.014 
F-IV 4.0±0.016 
F-V 4.0±0.012 
F-VI 4.0±0.017 
F-VII 4.0±0.004 
F-VIII 4.0±0.0181 
F-IX 4.0±0.015 
*Mean±SD (n=3) 
The thickness of the tablets is 4.00 mm. The tablets (F-I to F-IX) have uniform thickness. 
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4. Diameter: 
Diameter of various formulations is shown in Table 9.13. 
Tab. 9.13: Diameter of floating tablets 
Formulations Diameter* (mm) 
F-I 9.5±0.0 
F-II 9.5±0.0 
F-III 9.5±0.0 
F-IV 9.5±0.0 
F-V 9.5±0.0 
F-VI 9.5±0.0 
F-VII 9.5±0.0 
F-VIII 9.5±0.0 
F-IX 9.5±0.0 
*Mean±SD (n=3) 
The diameter of the tablets is 9.5 mm. The tablets (F-I to F-IX) have uniform diameter. 
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5. Hardness:  
The hardness of the floating tablets is given in Table 9.14. 
Tab. 9.14: Hardness of floating tablets 
Formulations Hardness* (kg/cm2) 
 
F-I 4.3±0.2236 
F-II 4.2±0.2236 
F-III 4.0±0.1095 
F-IV 4.2±0.1414 
F-V 4.1±0.0894 
F-VI 4.3±0.2236 
F-VII 4.3±0.3536 
F-VIII 4.0±0.2739 
F-IX 4.3±0.2608 
     *Mean±SD (n=3) 
The hardness of the tablets ranged from 4.0 kg/cm2 to 4.3 kg/cm2. The tablets (F-I to F-IX) 
have sufficient hardness to withstand transport and handling. 
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6. Friability: 
The friability of various formulations is given in Table 9.15. 
Tab. 9.15: Friability of floating tablets 
 
  
  
   
 
 
 
 
 
 
 
 
*Mean±SD (n=3) 
The percentage friability of various formulations ranged from 0.4012% to 0.6869%. The 
percentage friability is within the limit.58 
 
 
 
Formulations %Friability* 
F-I 0.6869±0.032 
F-II 0.5500±0.025 
F-III 0.5100±0.016 
F-IV 0.4012±0.027 
F-V 0.4213±0.014 
F-VI 0.5001±0.035 
F-VII 0.5224±0.022 
F-VIII 0.4991±0.011 
F-IX 0.6057±0.018 
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7. Drug content: 
 The content of active ingredient in various formulations is given in Table 9.16. 
Tab. 9.16: Drug content of tablets 
Formulations Drug content* (%w/w) 
F-I 97.6±2.3126 
F-II 98.1±1.5185 
F-III 98.3±1.3809 
F-IV 98.7±1.0251 
F-V 97.1±1.1638 
F-VI 97.2±0.9515 
F-VII 107.2±0.6368 
F-VIII 96.5±0.3609 
F-IX 95.8±0.8991 
*Mean±SD (n=5) 
The percentage of drug content ranged from 96.32%w/w to 99.22%w/w. All the formulations 
comply with the official standards.60 
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8. Swelling index 
The swelling index of various formulations is given in Table 9.17 
Formulations Swelling index (%) 
F-I 151 
F-II 165 
F-III 178 
F-IV 167 
F-V 176 
F-VI 190 
F-VII 175 
F-VIII 183 
F-IX 190 
 
Fig. 9.14: floating lag time of tablets 
a. At zero second   b.   At  2 min 58 sec 
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9. Buoyancy lag time and total floating time: 
The buoyancy lag time and total floating time of various formulations are given in table 
9.18 and fig.9.14 
Tab. 9.18: Buoyancy lag time of floating tablets 
Formulations Buoyancy lag time (min) Total floating time (hrs) 
F-I 2 min 58 sec >12 
F-II 3 min 0 sec >12 
F-III 2 min 59 sec >12 
F-IV 2 min 51 sec >12 
F-V 2 min 45 sec >12 
F-VI 2 min 50 sec >12 
F-VII 2 min 54 sec >12 
F-VIII 2 min 38 sec >12 
F-IX 2 min 57 sec >12 
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10. In vitro release study: 
The results of in vitro release study are shown in Table 9.19- 9.21 and fig. 9.15-9.17 
Tab. 9.19 : In vitro release study of tablets containing various concentrations of HPMC 
K4M  
Time in hrs Cumulative % drug release 
F-I F-II F-III 
0 0 ± 0.000 0 ± 0.0000 0 ± 0.0000 
1 32.8 ± 0.3562 30.9 ± 0.2223 30.2 ± 0.5632 
2 46.1 ± 0.1522 44.2 ± 0.3652 43.4 ± 0.2232 
3 53.4 ± 0.2564 50.4 ± 0.5621 49.9 ± 0.5698 
4 63.6 ± 0.3352 62.4 ± 0.8952 61.6 ± 0.5235 
5 70.8 ± 0.5265 69.2 ± 0.5621 67.4 ± 0.5122 
6 79.6 ± 0.5487 74.7 ± 0.5862 71.9 ± 0.5642 
7 86.4 ± 0.5648 85.2 ± 0.2635 78.9 ± 0.5312 
8 96.7 ± 0.3652  93.8 ± 0.5642 88.2 ± 1256 
9  97.9 ±0.2682 96.5 ± 0.5164 
 
Formulation F-I showed 96.7% drug release at the end of 8 hrs. The formulation F-II showed 
97.9% drug release at the end of 9 hrs and the formulation F-III showed 96.5% drug release at 
the end of 9 hrs. 
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Tab. 9.20: In vitro release study of tablets containing various concentrations of HPMC 
K100M  
Time in hrs Cumulative % drug release 
F-IV F-V F-VI 
0 0 ± 0.0000 0 ± 0.0000 0 ± 0.0000 
1 28.9 ± 0.1254 28 ± 0.1564 26.2 ± 0.0.5623 
2 40.7 ± 0.5682 38.9 ± 0.5623 36.4 ± 0.2564 
3 47.0 ± 0.4223 46.5 ± 0.2314 43.5 ± 0.3256 
4 58.3 ± 0.5214 57.3 ± 0.2651 53.2 ± 0.3652 
5 66.4 ± 0.1256 64.3 ± 0.2564 62.4 ± 0.5623  
6 69.9 ± 0.5463 67.9 ± 0.4698 65.2 ± 0.5623 
7 77.3 ± 0.5622 75.5 ± 0.5612 73.6 ± 0.5621 
8 85.9 ±0.5642 84 ± 0.6125 81.1 ± 0.4120 
9 93.7 ± 0.5312 93.3 ± 0.4562 88.8 ± 0.3256 
10 97.4 ± 0.4622 96.4 ± 0.5622 93.5 ± 0.5478 
11  98.8 ± 0.2563 96.1 ± 0.2356 
12   99.0 ± 0.4622 
 
Formulation F-IV showed 97.4% drug release at the end of 10 hrs. The formulation F-V 
showed 98.8% drug release at the end of 11 hrs and the formulation F-VI showed 99.0% drug 
release at the end of 12 hrs. 
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Table 9.21: In vitro release study of tablet containing various concentration of HPMC 
K4M and HPMC K100M  
Time in hrs Cumulative % drug release 
F –VII F –VIII F - IX 
0 0 ± 0.0000 0 ± 0.0000 0 ±  0.0000 
1 29.9 ± 0.5224 28.7 ± 0.4522 28.2 ± 0.2563 
2 42.6 ± 0.5456 41.3 ± 0.1562 38.6 ± 0.3652 
3 48.9 ± 0.6582 47.9 ± 0.2112 47.1 ± 0.4552 
4 58.9 ± 0.2541 56.4 ± 0.3562 56.1 ± 0.2589 
5 65.8 ± 0.4562 67.2 ± 6853 63.6 ± 0.2456 
6 70.9 ± 0.6524 72.7 ± 0.4562 67.1 ± 0.3654 
7 81.7 ± 0.5452 77.5 ± 0.3256 76.1 ± 0.1256 
8 89.7 ± 0.5641 85.6 ± 0.3652 85.2 ± 0.2564 
9 97.3 ± 0.4521 93.3 ± 0.3425 93.6 ± 0.2254 
10  98.4 ± 0.5461 96.9 ± 0.2561 
11   99.2 ± 0.1546 
 
Formulation F-VII showed 97.3% drug release at the end of 9 hrs. The formulation F-VIII 
showed 98.4% drug release at the end of 10 hrs and the formulation F-IX showed 99.2% drug 
release at the end of 11 hrs. 
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Fig.9.15: Cumulative percentage drug release of formulation F-I, F-II and F-III 
 
Fig.9.16: Cumulative percentage drug release of formulation F-IV, F-V and F-VI 
 
Fig; 9.17: Cumulative percentage drug release of formulation F-VII, F-VIII and F-IX 
 
 
                                                                                                             9. Results & Discussion 
 
Department of Pharmaceutics, Madras Medical College. Page 99 
 
Tab. 9.22: Release kinetics of the optimized formulation 
Time 
in 
hrs 
% 
cumulative 
drug 
release 
%cumulative 
drug 
remaining 
log 
%cumulative 
drug release 
Square 
root of 
time 
Log 
time 
log %cum 
drug 
remaining 
cube root 
of %drug 
remaining 
0 0 100 -α 0 -α 2 4.6415 
1 26.2 73.8 1.4183 1 0 1.8680 4.1945 
2 36.4 63.6 1.5611 1.4142 0.3010 1.8034 3.9916 
3 43.5 56.5 1.6384 1.73205 0.4771 1.7520 3.8372 
4 53.2 46.8 1.7259 2 0.6020 1.6702 3.6036 
5 62.4 37.6 1.7951 2.2360 0.6989 1.5751 3.3501 
6 65.2 34.8 1.8142 2.4494 0.7781 1.5415 3.2648 
7 73.6 26.4 1.8668 2.6457 0.8450 1.4216 2.9776 
8 81.1 18.9 1.9090 2.8284 0.9030 1.2764 2.6637 
9 88.8 11.2 1.9484 3 0.9542 1.0492 2.2373 
10 93.5 6.5 1.9708 3.1622 1 0.8129 1.8662 
11 96.1 3.9 1.9827 3.3166 1.0413 0.5910 1.574 
12 99 1 1.9956 3.4641 1.0791 0 1 
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Fig 9.18: Plot of Zero Order Release Kinetics 
 
 
Fig. 9.19: Plot of First Order Release Kinetics 
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Fig 9.20: Plot of Higuchi Kinetics 
 
 
Fig.9.21: Plot of Korsemeyer Peppas Kinetics 
 
   
 
 
                                                                                                             9. Results & Discussion 
 
Department of Pharmaceutics, Madras Medical College. Page 102 
 
Fig. 9.22: Plot of Hixson – Crowell Kinetics 
 
The plot of determination (R2) was taken as criteria for choosing the most appropriate model. 
The R2 values of various kinetic models are given in Table 9.23. 
Table 9.23: R2 values of various kinetic models 
Kinetic model Coefficient of 
determination (R2) 
Zero order 0.9493 
First order 0.8787 
Higuchi 0.9925 
Korsmeyer and Peppas 0.9942 
Hixson – Crowell 0.9751 
  
Among the various plots, it was clear that Zero order equation showed good linearity                        
(R2 =0.9493). Therefore in the present study, the in vitro release profiles of Betahistine were 
best described by Zero order release model followed by Korsemeyer – Peppas kinetics. The 
                                                                                                             9. Results & Discussion 
 
Department of Pharmaceutics, Madras Medical College. Page 103 
 
diffusion exponent of the solute n is 0.5599. Hence, the mechanism of drug release was found 
to be Anomalous non fickian transport. 
Stability studies 
The stability study results of optimized formulation is given in table 9.24 
Tab.9.24: Stability of optimized formulation (F-VI) 
S.No Temperature 40±2oC and RH 75±5% 
Parameter Month 1 Month 2 Month 3 
1 Uniformity of weight (g) 0.3025±0.0047 0.3021±0.0024 0.3019±0.0056 
2 Thickness (mm) 4.0±0.017 4.0±0.0151 4.0±0.0251 
3 Diameter (mm) 9.5±0.0 9.5±0.0000 9.5±0.0000 
4 Hardness (kg/cm2) 4.3±0.2236 4.2±0.1256 4.4±0.2546 
5 % friability 0.5001±0.035 0.4985±0.015 0.5142±0.1256 
6 Floating lag time 2 min 50 sec 2 min 45 sec 2 min 58 sec 
7 Total floating time >12 hrs >12 hrs >12 hrs 
8 Drug content (% w/w) 97.2±0.9515 97.4±0.8568 97.0±0.5623 
9 In vitro drug release at the 
end of 12 hrs (% w/w) 
98.0 ± 0.4622 97.9±0.5642 98.4±0.2315 
 
From the above results, it is observed that the optimized formulation maintains the stability 
for 3 months. 
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SUMMARY  
The Betahistine hydrochloride was successfully formulated into controlled release floating 
tablets using various grades of matrix-forming polymer such as HPMC K4M, HPMC K100M 
and its combination by wet granulation method.  
 Preformulation studies were performed for powder blends. 
 Physical compatibility study showed that the drug and excipients are physically 
compatible with each other. 
 Chemical compatibility study was performed using FTIR spectroscopy and FTIR 
studies revealed that there was no change in major peaks thus confirming no 
interaction between the drug and excipients. 
 Betahistine hydrochloride powder blend had passable flow property which was 
substantiated by bulk density, tapped density, compressibility index, Hausner’s ratio 
and angle of repose. Hence, the floating tablets of Betahistine hydrochloride were 
prepared by wet granulation method. 
 The post compression parameters of tablets were evaluated and the results were found 
to comply within limit. 
 The buoyancy lag time of all formulations were less than 3 min. 
 The total floating time of all formulations were more than 12 hrs. 
 The in vitro release studies were performed for all the formulations. Formulation F-VI 
containing 60% of HPMC K 100 M released 99.0% at the end of 12 hrs. Therefore, F-
VI was chosen as the optimized formulation. 
 The dissolution data of the optimized formulation were fitted to various kinetic models 
and the formulation F-VI fitted best to Zero order release kinetics. The mechanism of 
drug release was found to be diffusion, dissolution and swelling. 
From the overall results, it is clear that the formulation F-VI containing 60% of HPMC 
K 100 M is the optimal formulation among the other formulations, as it produced 
controlled drug release than other formulations. 
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CONCLUSION 
 The floating tablets of Betahistine hydrochloride may be useful over conventional 
system for effective treatment of vertigo in Meniere’s disease. 
 The floating tablets of Betahistine hydrochloride may be administered twice daily 
instead of four times a day.  
FUTURE SCOPE 
• Long term Stability studies for the optimized formulation as per the current ICH 
guidelines. 
• Pharmacokinetic and toxicity study. 
• Scale up studies for the optimized formulation. 
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